

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
1 February 2001 (01.02.2001)

PCT

(10) International Publication Number
WO 01/07052 A1

(51) International Patent Classification⁷: **A61K 31/55**

55 Mill Plain Road #32-11, Danbury, CT 06811 (US).
KUZMICH, Daniel; 4 Driftway Road, Unit C1, Danbury,
CT 06811 (US).

(21) International Application Number: **PCT/US00/17752**

(74) Agents: RAYMOND, Robert, P. et al.; Boehringer Ingelheim Corporation, 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT 06877 (US).

(22) International Filing Date: 28 June 2000 (28.06.2000)

(81) Designated States (national): CA, JP, MX.

(25) Filing Language: English

(84) Designated States (regional): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

(26) Publication Language: English

Published:

— With international search report.

(30) Priority Data:
60/144,894 21 July 1999 (21.07.1999) US


For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(71) Applicant: BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. [US/US]; 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT 06877 (US).

(72) Inventors: KELLY, Terence, Alfred; 66 Overlook Drive, Ridgefield, CT 06877 (US). WU, Jiang-Ping;



(54) Title: SMALL MOLECULES USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASE



(57) Abstract: Novel compounds of formula (I) which are useful for treating or preventing inflammatory and immune cell-mediated diseases. Exemplary compounds are: 2-(3,5-Dichlorophenyl)-7-(R*-phenyl-7a-(R*)-tetrahydropyrrolo[1,2-c]imidazole-1,3-dione; 2-(3,5-Dichlorophenyl)-7a-(R*-methyl-7-(R*)-phenyl-tetrahydropyrrolo[1,2-c]imidazole-1,3-dione; and, 7-(R*)(4-Bromophenyl)-2-(3,5-dichlorophenyl)-7a-(R*)-tetrahydropyrrolo[1,2-c]imidazole-1,3-dione.

Title of the Invention**SMALL MOLECULES****USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASE**5 **Field of the Invention**

The present invention relates generally to a series of novel small molecules, their synthesis and their use in the treatment of inflammatory disease.

Background of the Invention

- 10 Research spanning the last decade has helped to elucidate the molecular events attending cell-cell interactions in the body, especially those events involved in the movement and activation of cells in the immune system. See generally, Springer, T. *Nature*, 1990, 346, 425-434. Cell surface proteins, and especially the Cellular Adhesion Molecules ("CAMs") and "Leukointegrins", including LFA-1, MAC-1 and gp150.95 (referred to in WHO
15 nomenclature as CD18/CD11a, CD18/CD11b, and CD18/CD11c, respectively) have correspondingly been the subject of pharmaceutical research and development having as its goal the intervention in the processes of leukocyte extravasation to sites of injury and leukocyte movement to distinct targets. For example, it is presently believed that prior to the leukocyte extravasation, which is a mandatory component of the inflammatory
20 response, activation of integrins constitutively expressed on leukocytes occurs and is followed by a tight ligand/receptor interaction between integrins (e.g., LFA-1) and one or several distinct intercellular adhesion molecules (ICAMs) designated ICAM-1, ICAM-2, ICAM-3 or ICAM-4 which are expressed on blood vessel endothelial cell surfaces and on other leukocytes. The interaction of the CAMs with the Leukointegrins is a vital step in
25 the normal functioning of the immune system. Immune processes such as antigen presentation, T-cell mediated cytotoxicity and leukocyte extravasation all require cellular adhesion mediated by ICAMs interacting with the Leukointegrins. See generally Kishimoto, T. K.; Rothlein; R. R. *Adv. Pharmacol.* 1994, 25, 117-138 and Diamond, M.; Springer, T. *Current Biology*, 1994, 4, 506-532.
30 A group of individuals has been identified which lack the appropriate expression of Leukointegrins, a condition termed "Leukocyte Adhesion Deficiency" (Anderson, D. C.; et al., *Fed. Proc.* 1985, 44, 2671-2677 and Anderson, D. C.; et al., *J. Infect. Dis.* 1985, 152,

668-689). These individuals are unable to mount a normal inflammatory and/or immune response(s) due to an inability of their cells to adhere to cellular substrates. These data show that immune reactions are mitigated when lymphocytes are unable to adhere in a normal fashion due to the lack of functional adhesion molecules of the CD18 family. By 5 virtue of the fact that LAD patients who lack CD18 cannot mount an inflammatory response, it is believed that antagonism of CD18, CD11/ICAM interactions will also inhibit an inflammatory response.

It has been demonstrated that the antagonism of the interaction between the CAMs and the 10 Leukointegrins can be realized by agents directed against either component. Specifically, blocking of the CAMs, such as for example ICAM-1, or the Leukointegrins, such as for example LFA-1, by antibodies directed against either or both of these molecules effectively inhibits inflammatory responses. *In vitro* models of inflammation and immune response inhibited by antibodies to CAMs or Leukointegrins include antigen or mitogen-induced lymphocyte proliferation, homotypic aggregation of lymphocytes, T-cell mediated cytotoxicity and antigen-specific induced tolerance. The relevance of the *in vitro* studies are supported by *in vivo* studies with antibodies directed against ICAM-1 or LFA-1. For 15 example, antibodies directed against LFA-1 can prevent thyroid graft rejection and prolong heart allograft survival in mice (Gorski, A.; *Immunology Today*, 1994, 15, 251-255). Of greater significance, antibodies directed against ICAM-1 have shown efficacy *in vivo* as 20 anti-inflammatory agents in human diseases such as renal allograft rejection and rheumatoid arthritis (Rothlein, R. R.; Scharschmidt, L., in: *Adhesion Molecules*; Wegner, C. D., Ed.; 1994, 1-38, Cosimi, C. B.; *et al.*, *J. Immunol.* 1990, 144, 4604-4612 and Kavanaugh, A.; *et al.*, *Arthritis Rheum.* 1994, 37, 992-1004) and antibodies directed 25 against LFA-1 have demonstrated immunosuppressive effects in bone marrow transplantation and in the prevention of early rejection of renal allografts (Fischer, A.; *et al.*, *Lancet*, 1989, 2, 1058-1060 and Le Mauff, B.; *et al.*, *Transplantation*, 1991, 52, 291-295).

30 It has also been demonstrated that a recombinant soluble form of ICAM-1 can act as an inhibitor of the ICAM-1 interaction with LFA-1. Soluble ICAM-1 acts as a direct antagonist of CD18,CD11/ICAM-1 interactions on cells and shows inhibitory activity in *in vitro* models of immune response such as the human mixed lymphocyte response,

cytotoxic T cell responses and T cell proliferation from diabetic patients in response to islet cells (Becker, J. C.; *et al.*, *J. Immunol.* 1993, 151, 7224 and Roep, B. O.; *et al.*, *Lancet*, 1994, 343, 1590).

5 Thus, the prior art has demonstrated that large protein molecules which antagonize the binding of the CAMs to the Leukointegrins have therapeutic potential in mitigating inflammatory and immunological responses often associated with the pathogenesis of many autoimmune or inflammatory diseases. However proteins have significant deficiencies as therapeutic agents, including the inability to be delivered orally and
10 potential immunoreactivity which limits the utility of these molecules for chronic administration. Furthermore, protein-based therapeutics are generally expensive to produce.

Several small molecules have been described in the literature which affect the interaction
15 of CAMs and Leukointegrins. A natural product isolated from the root of *Trichilia rubra* was found to be inhibitory in an *in vitro* cell binding assay (Musza, L. L.; *et al.*, *Tetrahedron*, 1994, 50, 11369-11378). One series of molecules (Boschelli, D. H.; *et al.*, *J. Med. Chem.* 1994, 37, 717 and Boschelli, D. H.; *et al.*, *J. Med. Chem.* 1995, 38, 4597-
20 4614) was found to be orally active in a reverse passive Arthus reaction, an induced model of inflammation that is characterized by neutrophil accumulation (Chang, Y. H.; *et al.*, *Eur. J. Pharmacol.* 1992, 69, 155-164). Another series of molecules was also found to be orally active in a delayed type hypersensitivity reaction in rats (Sanfilippo, P. J.; *et al.*, *J. Med. Chem.* 1995, 38, 1057-1059). All of these molecules appear to act nonspecifically, either by inhibiting the transcription of ICAM-1 along with other proteins or act
25 intracellularly to inhibit the activation of the Leukointegrins by an unknown mechanism. None of the molecules directly antagonize the interaction of the CAMs with the Leukointegrins. Due to lack of potency, lack of selectivity and lack of a specific mechanism of action, the described small molecules are not likely to be satisfactory for therapeutic use.

30 It follows that small molecules having the similar ability as large protein molecules to directly and selectively antagonize the binding of the CAMs to the Leukointegrins would make preferable therapeutic agents. WO9839303 discloses a class of small molecule

inhibitors of the interaction of LFA-1 and ICAM-1. WO9911258 discloses that the fungal metabolite mevinolin and derivatives bind to LFA-1 and disrupt the interaction of LFA-1 and ICAM-1.


5 Summary of the Invention

A first aspect of the invention comprises a method for treating or preventing inflammatory and immune cell-mediated diseases by the administration of certain novel small molecules. These compounds act by inhibiting the interaction of cellular adhesion molecules, specifically by antagonizing the binding of human intercellular adhesion molecules 10 (including ICAM-1, ICAM-2 and ICAM-3) to the Leukointegrins (especially CD18/CD11a). A second aspect of the invention comprises novel small molecules having the above-noted therapeutic activities. A third aspect of the invention comprises methods for making these novel compounds. A final aspect of the invention comprises pharmaceutical compositions comprising the above-mentioned compounds suitable for the 15 prevention or treatment of inflammatory and immune cell-mediated conditions.

Detailed Description of the Invention

The invention comprises compounds of the formula I

20



wherein:

25

m is 0 or 1,

n is 0 or 1, and

m + n is equal to either 1 or 2;

5 Y is an oxygen or sulfur atom;

Z is an oxygen or sulfur atom;

R¹ is:

10

- (A) a hydrogen atom, or
- (B) branched or unbranched alkyl of 1 to 3 carbon atoms or cycloalkyl of 3 to 5 carbon atoms wherein said alkyl or cycloalkyl group may optionally be substituted with:
 - (i) a group of the formula -OR¹⁰, wherein R¹⁰ is an alkyl or acyl group of 1 to 2 carbon atoms,
 - (ii) a group of the formula -NR¹¹R¹², wherein R¹¹ and R¹² are each, independently, alkyl of 1 to 2 carbon atoms, or acyl of 1 to 2 carbon atoms, or
- (C) a group of the formula -OR¹³, wherein R¹³ is a an alkyl or acyl group of 1 to 2 carbon atoms;

25 R² is:

aryl selected from the class consisting of phenyl, 2-naphthyl, 2-, 3-, 5- or 6-indolyl, 2- or 3-thiophenyl, 2-, 3- or 4-pyridyl, 2-, 4- or 5-pyrimidinyl, 2- or 3-furyl, 1-, 2- or 3-pyrrolyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, 1-, 3-, 4- or 5-pyrazolyl, 3-, 4- or 5-isoxazolyl, 1-, 2-, 4- or 5-imidazolyl, 3-, 4- or 5-isothiazolyl, 4- or 5-oxadiazolyl, 1-, 4- or 5-triazolyl, 2-thiadiazolyl, 3- or 4-pyridazinyl, 2-pyrazinyl, 2-

5 triazinyl, 2-, 3-, 6- or 7-indolyzinyl, 2-, 3-, 5- or 6-isoindolyl, 2-, 3-, 5- or 6-benzo[b]furanyl, 2-, 3-, 5- or 6-benzo[b]thiophenyl, 3-, 5- or 6-indazolyl, 2-, 5- or 6-benzthiazolyl, 2-, 5- or 6-benzimidazolyl, 2-, 3-, 6- or 7-quinolinyl, 3-, 6- or 7-isoquinolinyl, 2- or 8-purinyl, 2-, 3-, 7- or 8-quinolizinyl, 3-, 6- or 7-cinnolinyl, 6- or 7-pthalaninyl, 2-, 3-, 6- or 7-quinoxalinyl, 2-, 3-, 6- or 7-naphthyridinyl, 2-, 6- or 7-pteridinyl and 2-, 6- or 7-quinazolinyl,

wherein one or more of the hydrogen atoms of said aryl group may be optionally and independently replaced with:

10

- (i) R¹⁴, which is aryl selected from the class consisting of phenyl, 2-naphthyl, 2-, 3-, 5- or 6-indolyl, 2- or 3-thiophenyl, 2-, 3- or 4-pyridyl, 2-, 4- or 5-pyrimidinyl, 2- or 3-furyl, 1-, 2- or 3-pyrrolyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, 1-, 3-, 4- or 5-pyrazolyl, 3-, 4- or 5-isoxazolyl, 1-, 2-, 4- or 5-imidazolyl, 3-, 4- or 5-isothiazolyl, 4- or 5-oxadiazolyl, 1-, 4- or 5-triazolyl, 2-thiadiazolyl, 3- or 4-pyridazinyl, 2-pyrazinyl, 2-triazinyl, 2-, 3-, 6- or 7-indolyzinyl, 2-, 3-, 5- or 6-isoindolyl, 2-, 3-, 5- or 6-benzo[b]furanyl, 2-, 3-, 5- or 6-benzo[b]thiophenyl, 3-, 5- or 6-indazolyl, 2-, 5- or 6-benzthiazolyl, 2-, 5- or 6-benzimidazolyl, 2-, 3-, 6- or 7-quinolinyl, 3-, 6- or 7-isoquinolinyl, 2- or 8-purinyl, 2-, 3-, 7- or 8-quinolizinyl, 3-, 6- or 7-cinnolinyl, 6- or 7-pthalaninyl, 2-, 3-, 6- or 7-quinoxalinyl, 2-, 3-, 6- or 7-naphthyridinyl, 2-, 6- or 7-pteridinyl and 2-, 6- or 7-quinazolinyl,

wherein one or more of the hydrogen atoms of said R¹⁴ aryl group may be optionally and independently replaced with:

20

- (a) branched or unbranched alkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, which alkyl or cycloalkyl group may be mono- or polysubstituted with halogen or oxo,

(b) a group of the formula $-COOR^{15}$, wherein R¹⁵ is straight or branched alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,

5

(c) a group of the formula $-NR^{16}R^{17}$, wherein R¹⁶ and R¹⁷ are each, independently, a hydrogen atom, alkyl or fluoroalkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms or acyl of 1 to 7 carbon atoms, or wherein R¹⁶ and R¹⁷ constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom between them form a heterocyclic ring,

10

(d) a group of the formula $-CONR^{18}R^{19}$, wherein R¹⁸ and R¹⁹ are each independently a hydrogen atom, alkyl or fluoroalkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, or wherein R¹⁸ and R¹⁹ constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom between them form a heterocyclic ring,

20

(e) a group of the formula $-OR^{20}$, wherein R²⁰ is a hydrogen atom, or an alkyl, fluoroalkyl or acyl group of 1 to 7 carbon atoms,

25

(f) a group of the formula $-SR^{21}$, wherein R²¹ is a hydrogen atom, or an alkyl, fluoroalkyl or acyl group of 1 to 7 carbon atoms,

30

(g) cyano,

- (h) nitro,
- (i) halogen,
- (ii) methyl, which may be mono- or polysubstituted with fluorine atoms,
- (iii) branched or unbranched alkyl of 2 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, which alkyl or cycloalkyl group may be mono- or polysubstituted with halogen or oxo,
- (iv) a group of the formula $-COOR^{22}$, wherein R^{22} is straight or branched alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,
- (v) a group of the formula $-NR^{23}R^{24}$, wherein R^{23} and R^{24} are each, independently, a hydrogen atom, alkyl or fluoroalkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms or acyl of 1 to 7 carbon atoms, or wherein R^{23} and R^{24} constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom between them form a heterocyclic ring,
- (vi) a group of the formula $-CONR^{25}R^{26}$, wherein R^{25} and R^{26} are each, independently, a hydrogen atom, alkyl or fluoroalkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, or wherein R^{25} and R^{26} constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom between them form a heterocyclic ring,

- (vii) a group of the formula $-COR^{27}$, wherein R²⁷ is a hydrogen atom, straight or branched alkyl of 1 to 5 carbon atoms, or cycloalkyl of 3 to 5 carbon atoms,
- 5 (viii) a group of the formula $-OR^{28}$, wherein R²⁸ is a hydrogen atom, an alkyl, fluoroalkyl or acyl group of 1 to 7 carbon atoms,
- 10 (ix) a group of the formula $-SR^{29}$, wherein R²⁹ is a hydrogen atom, an alkyl, fluoroalkyl or acyl group of 1 to 7 carbon atoms,
- (x) cyano,
- 15 (xi) nitro, or
- (xii) halogen,

R³ is:

- 20 (A) a hydrogen atom, or
- (B) branched or unbranched alkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms wherein said alkyl or cycloalkyl group may optionally be substituted with:
- 25 (i) a group of the formula $-OR^{30}$, wherein R³⁰ is a hydrogen atom, or an alkyl or acyl group of 1 to 6 carbon atoms,
- 30 (ii) a group of the formula $-NR^{31}R^{32}$, wherein R³¹ and R³² are each, independently, a hydrogen atom, alkyl of 1 to 6 carbon atoms, or acyl of 1 to 6 carbon atoms, or

(C) a group of the formula $-OR^{33}$, wherein R^{33} is a hydrogen atom, or an alkyl or acyl group of 1 to 6 carbon atoms;

5

R^4 is Cl or trifluoromethyl;

X is =N- or =CR⁵-,

wherein R⁵ is a hydrogen, fluorine, chlorine, bromine or iodine atom, methyl or
10 trifluoromethyl;

R^6 is a hydrogen, fluorine, chlorine, bromine or iodine atom, methyl, cyano, nitro or trifluoromethyl, with the condition that when X is N or =CH-, R^6 is chlorine or trifluoromethyl;

15

R^7 , R^8 and R^9 are each, independently:

(A) a hydrogen atom,

20 (B) an oxo group, or

(C) R^{34} , OR^{34} , NHR^{34} , COR^{34} , $CONHR^{34}$, $COOR^{34}$, SO_2R^{34} , or SR^{34}

wherein R^{34} is defined as:

25

(i) A hydrogen atom,

(ii) branched or unbranched alkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, which alkyl or cycloalkyl group may be mono- or polysubstituted with:


30

(a) halogen,

- (b) oxo,
- (c) aryl which is selected from the class consisting of phenyl,
naphthyl, indolyl, thiophenyl, pyridyl, pyrimidinyl, furyl,
5 pyrrolyl, oxazolyl, thiazolyl, pyrazolyl, isoxazolyl,
imidazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl,
pyridazinyl, pyrazinyl, triazinyl, indolyzinyl, isoindolyl,
benzo[b]furanyl, benzo[b]thiophenyl, indazolyl,
10 benzthiazolyl, benzimidazolyl, quinolinyl, isoquinolinyl,
purinyl, quinolizinyl, cinnolinyl, phthalaninyl, quinoxalinyl,
naphthyridinyl, pteridinyl and quinazolinyl,
- wherein one or more hydrogen atoms of said aryl group may
be optionally and independently replaced with:
- 15 (1) alkyl of 1 to 3 carbon atoms,
- (2) -COOH,
- 20 (3) -SO₂OH,
- (4) -PO(OH)₂,
- 25 (5) a group of the formula -COOR³⁵, wherein R³⁵ is
straight or branched alkyl of 1 to 5 carbon atoms or
cycloalkyl of 3 to 5 carbon atoms,
- (6) a group of the formula -NR³⁶R³⁷, wherein R³⁶ and
R³⁷ are each independently a hydrogen atom, alkyl
30 of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon
atoms or acyl of 1 to 7 carbon atoms, or wherein R³⁶
and R³⁷ constitute a saturated hydrocarbon bridge of

3 to 5 carbon atoms which together with the nitrogen atom between them form a heterocyclic ring,

- (7) a group of the formula $-\text{CONR}^{38}\text{R}^{39}$, wherein R^{38} and R^{39} are each independently a hydrogen atom, alkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, or wherein R^{38} and R^{39} constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom between them form a heterocyclic ring,
- (8) a group of the formula $-\text{OR}^{40}$, wherein R^{40} is a hydrogen atom, or an alkyl or acyl group of 1 to 7 carbon atoms,
- (9) a group of the formula $-\text{SR}^{41}$, wherein R^{41} is a hydrogen atom, or an alkyl or acyl group of 1 to 7 carbon atoms,
- (10) cyano, or
- (11) an amidino group of the formula



wherein R^{42} , R^{43} and R^{44} are each, independently, a hydrogen atom or alkyl of 1 to 3 carbon atoms and wherein two of R^{42} , R^{43} and R^{44} may additionally constitute a saturated hydrocarbon bridge of 3 to 5

carbon atoms which together with the nitrogen atom(s) between them form a heterocyclic ring,

- 5 (d) a group of the formula $-COOR^{45}$, wherein R⁴⁵ is straight or branched alkyl of 1 to 7 carbon atoms or cycloalkyl of 3 to 6 carbon atoms,

10 (e) cyano,

15 (f) a group of the formula $-CONR^{46}R^{47}$, wherein R⁴⁶ and R⁴⁷ are each, independently, a hydrogen atom, alkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, or wherein R⁴⁶ and R⁴⁷ constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom between them form a heterocyclic ring,

20 (g) a group of the formula $-OR^{48}$, wherein R⁴⁸ is a hydrogen atom, or an alkyl or acyl group of 1 to 7 carbon atoms,

25 (h) a group of the formula $-SR^{49}$, wherein R⁴⁹ is a hydrogen atom, or an alkyl or acyl group of 1 to 7 carbon atoms,

(i) a group of the formula $-NR^{50}R^{51}$, wherein R⁵⁰ and R⁵¹ are each, independently,

(1) a hydrogen atom,

(2) alkyl or acyl of 1 to 7 carbon atoms or cycloalkyl of 3 to 7 carbon atoms,

30 (3) a group of the formula $-(CH_2)_tCOOH$, wherein t is 0, 1 or 2, or


- (4) a group of the formula $-(\text{CH}_2)_u\text{COOR}^{52}$, wherein u is 0, 1 or 2, wherein R^{52} is straight or branched alkyl of 1 to 6 carbon atoms,

5

or wherein R^{50} and R^{51} constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom between them form a heterocyclic ring, or

10

- (j) a quaternary group of the formula



15

wherein R^{53} , R^{54} and R^{55} are each, independently, a branched or unbranched alkyl group of 1 to 7 carbon atoms and Q^- is a chlorine, bromine or iodine counterion,

20


- (iii) a branched or unbranched carboxylic acid group of 2 to 6 carbon atoms,

25

- (iv) a branched or unbranched phosphonic acid group of 2 to 6 carbon atoms,

- (v) a branched or unbranched sulfonic acid group of 2 to 6 carbon atoms,

- (vi) an amidino group of the formula




wherein r is 2, 3, 4, 5 or 6, and

R⁵⁶, R⁵⁷ and R⁵⁸ are each, independently, a hydrogen atom or alkyl of 1 to 3 carbon atoms, and wherein two of R⁵⁶, R⁵⁷ and R⁵⁸ may additionally constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom(s) between them form a heterocyclic ring,

5

(vii) a guanidino group of the formula



10

wherein s is 2, 3, 4, 5 or 6, and

15

R⁵⁹, R⁶⁰, R⁶¹ and R⁶² are each, independently, a hydrogen atom or alkyl of 1 to 3 carbon atoms, and wherein two of R⁵⁹, R⁶⁰, R⁶¹ and R⁶² may additionally constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom(s) between them form a heterocyclic ring,

20

(viii) aryl which is selected from the class consisting of phenyl, naphthyl, indolyl, thiophenyl, pyridyl, pyrimidinyl, furyl, pyrrolyl, oxazolyl, thiazolyl, pyrazolyl, isoxazolyl, imidazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyridazinyl, pyrazinyl, triazinyl, indolyzinyl, isoindolyl, benzo[b]furanyl, benzo[b]thiophenyl, indazolyl, benzthiazolyl, benzimidazolyl, quinolinyl, isoquinolinyl, purinyl, quinolizinyl, cinnolinyl, pthalaninyl, quinoxalinyl, naphthyridinyl, pteridinyl and quinazolinyl,

25

wherein one or more hydrogen atoms of said aryl group may be optionally and independently replaced with:

- 5 (a) alkyl of 1 to 3 carbon atoms,

10 (b) -COOH,

15 (c) -SO₂OH,


20 (d) -PO(OH)₂,

25 (e) a group of the formula -COOR⁶³, wherein R⁶³ is straight or branched alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,

30 (f) a group of the formula -NR⁶⁴R⁶⁵, wherein R⁶⁴ and R⁶⁵ are each, independently, a hydrogen atom, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms or acyl of 1 to 7 carbon atoms, or wherein R⁶⁴ and R⁶⁵ constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom between them form a heterocyclic ring,

35 (g) a group of the formula -CONR⁶⁶R⁶⁷, wherein R⁶⁶ and R⁶⁷ are each, independently, a hydrogen atom, alkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, or wherein R⁶⁶ and R⁶⁷ constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom between them form a heterocyclic ring,

- (h) a group of the formula $-OR^{68}$, wherein R⁶⁸ is a hydrogen atom, or an alkyl or acyl group of 1 to 7 carbon atoms,
- 5 (i) a group of the formula $-SR^{69}$, wherein R⁶⁹ is a hydrogen atom, or an alkyl or acyl group of 1 to 7 carbon atoms,
- (j) cyano,
- 10 (k) or, an amidino group of the formula



15 wherein R⁷⁰, R⁷¹ and R⁷² are each, independently, a hydrogen atom or alkyl of 1 to 3 carbon atoms, and wherein two of R⁷⁰, R⁷¹ and R⁷² may additionally constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom(s) between them form a heterocyclic ring;

20 with the proviso that R¹ and R² are in the trans configuration.

and pharmaceutically acceptable salts thereof.

25 Preferred are compounds of the formula I, wherein:

m is 0 or 1,

n is 0 or 1, and

m + n is equal to either 1 or 2;

Y is an oxygen or sulfur atom;

5

Z is an oxygen or sulfur atom;

R¹ is:

10 (A) a hydrogen atom, or

(B) branched or unbranched alkyl of 1 to 3 carbon atoms or cycloalkyl of 3 to 5 carbon atoms wherein said alkyl or cycloalkyl group may optionally be substituted with:

15

(i) a group of the formula -OR¹⁰, wherein R¹⁰ is an alkyl or acyl group of 1 to 2 carbon atoms,

20 (ii) a group of the formula -NR¹¹R¹², wherein R¹¹ and R¹² are each, independently, alkyl of 1 to 2 carbon atoms, or acyl of 1 to 2 carbon atoms, or

(C) a group of the formula -OR¹³, wherein R¹³ is a an alkyl or acyl group of 1 to 2 carbon atoms;

25

R² is:

aryl selected from the class consisting of phenyl, 2-naphthyl, 2-, 3-, 5- or 6-indolyl, 2- or 3-thiophenyl, 2-, 3- or 4-pyridyl, 2-, 4- or 5-pyrimidinyl, 2- or 3-furyl, 1-, 2- or 3-pyrrolyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, 1-, 3-, 4- or 5-pyrazolyl, 3-, 4- or 5-isoxazolyl, 1-, 2-, 4- or 5-imidazolyl, 3-, 4- or 5-isothiazolyl, 4- or 5-oxadiazolyl, 1-, 4- or 5-triazolyl, 2-thiadiazolyl, 3- or 4-pyridazinyl, 2-pyrazinyl, 2-triazinyl, 2-, 3-, 6- or 7-indolizinyl, 2-, 3-, 5- or 6-isoindolyl, 2-, 3-, 5- or 6-

benzo[b]furanyl, 2-, 3-, 5- or 6-benzo[b]thiophenyl, 3-, 5- or 6-indazolyl, 2-, 5- or 6-benzthiazolyl, 2-, 5- or 6-benzimidazolyl, 2-, 3-, 6- or 7-quinolinyl, 3-, 6- or 7-isoquinolinyl, 2- or 8-purinyl, 2-, 3-, 7- or 8-quinolizinyl, 3-, 6- or 7-cinnolinyl, 6- or 7-pthalaninyl, 2-, 3-, 6- or 7-quinoxalinyl, 2-, 3-, 6- or 7-naphthyridinyl, 2-, 6- or 7-pteridinyl and 2-, 6- or 7-quinazolinyl,

5

wherein one or more of the hydrogen atoms of said aryl group may be optionally and independently replaced with:

10

(i) R^{14} , which is aryl selected from the class consisting of phenyl, 2-naphthyl, 2-, 3-, 5- or 6-indolyl, 2- or 3-thiophenyl, 2-, 3- or 4-pyridyl, 2-, 4- or 5-pyrimidinyl, 2- or 3-furyl, 1-, 2- or 3-pyrrolyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, 1-, 3-, 4- or 5-pyrazolyl, 3-, 4- or 5-isoxazolyl, 1-, 2-, 4- or 5-imidazolyl, 3-, 4- or 5-isothiazolyl, 4- or 5-oxadiazolyl, 1-, 4- or 5-triazolyl, 2-thiadiazolyl, 3- or 4-pyridazinyl, 2- pyrazinyl, 2-triazinyl, 2-, 3-, 6- or 7-indolyzinyl, 2-, 3-, 5- or 6-isoindolyl, 2-, 3-, 5- or 6-benzo[b]furanyl, 2-, 3-, 5- or 6-benzo[b]thiophenyl, 3-, 5- or 6-indazolyl, 2-, 5- or 6-benzthiazolyl, 2-, 5- or 6-benzimidazolyl, 2-, 3-, 6- or 7-quinolinyl, 2- or 8-purinyl, 2-, 3-, 7- or 8-quinolizinyl, 3-, 6- or 7-cinnolinyl, 6- or 7-pthalaninyl, 2-, 3-, 6- or 7-quinoxalinyl, 2-, 3-, 6- or 7-naphthyridinyl, 2-, 6- or 7-pteridinyl and 2-, 6- or 7-quinazolinyl,

15

20

25

wherein one or more of the hydrogen atoms of said R^{14} aryl group may be optionally and independently replaced with:

30

(a) branched or unbranched alkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, which alkyl or cycloalkyl group may be mono- or polysubstituted with halogen or oxo,

- (b) a group of the formula $-COOR^{15}$, wherein R¹⁵ is straight or branched alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,
- 5 (c) a group of the formula $-NR^{16}R^{17}$, wherein R¹⁶ and R¹⁷ are each, independently, a hydrogen atom, alkyl or fluoroalkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms or acyl of 1 to 7 carbon atoms, or wherein R¹⁶ and R¹⁷ constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom between them form a heterocyclic ring,
- 10 (d) a group of the formula $-CONR^{18}R^{19}$, wherein R¹⁸ and R¹⁹ are each independently a hydrogen atom, alkyl or fluoroalkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, or wherein R¹⁸ and R¹⁹ constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom between them form a heterocyclic ring,
- 15 (e) a group of the formula $-OR^{20}$, wherein R²⁰ is a hydrogen atom, or an alkyl, fluoroalkyl or acyl group of 1 to 7 carbon atoms,
- 20 (f) a group of the formula $-SR^{21}$, wherein R²¹ is a hydrogen atom, or an alkyl, fluoroalkyl or acyl group of 1 to 7 carbon atoms,
- 25 (g) cyano,
- (h) nitro,

- (i) halogen,
- (ii) methyl, which may be mono- or polysubstituted with
5 fluorine atoms,
- (iii) branched or unbranched alkyl of 2 to 6 carbon atoms or
cycloalkyl of 3 to 6 carbon atoms, which alkyl or cycloalkyl
group may be mono- or polysubstituted with halogen or oxo,
- 10 (iv) a group of the formula $-COOR^{22}$, wherein R²² is straight or
branched alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5
carbon atoms,
- 15 (v) a group of the formula $-NR^{23}R^{24}$, wherein R²³ and R²⁴ are
each, independently, a hydrogen atom, alkyl or fluoroalkyl of
1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms or
acyl of 1 to 7 carbon atoms, or wherein R²³ and R²⁴
constitute a saturated hydrocarbon bridge of 3 to 5 carbon
atoms which together with the nitrogen atom between them
form a heterocyclic ring,
- 20 (vi) a group of the formula $-CONR^{25}R^{26}$, wherein R²⁵ and R²⁶
are each, independently, a hydrogen atom, alkyl or
fluoroalkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6
carbon atoms, or wherein R²⁵ and R²⁶ constitute a saturated
hydrocarbon bridge of 3 to 5 carbon atoms which together
with the nitrogen atom between them form a heterocyclic
ring,

25
30

- (vii) a group of the formula $-COR^{27}$, wherein R²⁷ is a hydrogen atom, straight or branched alkyl of 1 to 5 carbon atoms, or cycloalkyl of 3 to 5 carbon atoms,
- 5 (viii) a group of the formula $-OR^{28}$, wherein R²⁸ is a hydrogen atom, an alkyl, fluoroalkyl or acyl group of 1 to 7 carbon atoms,
- 10 (ix) a group of the formula $-SR^{29}$, wherein R²⁹ is a hydrogen atom, an alkyl, fluoroalkyl or acyl group of 1 to 7 carbon atoms,
- (x) cyano,
- 15 (xi) nitro, or
- (xii) halogen,

R³ is:

- 20 (A) a hydrogen atom,
- (B) methyl, or
- 25 (C) a group of the formula $-OR^{33}$, wherein R³³ is a hydrogen atom methyl;

R⁴ is Cl or trifluoromethyl;

X is =N- or =CR⁵-,

- 30 wherein R⁵ is a hydrogen, fluorine, chlorine, bromine or iodine atom, methyl or trifluoromethyl;

R^6 is a hydrogen, fluorine, chlorine, bromine or iodine atom, methyl, cyano, nitro or trifluoromethyl, with the condition that when X is N or =CH-, R^6 is chlorine or trifluoromethyl;

5 R^7 , R^8 and R^9 are each, independently:


- (A) a hydrogen atom,
- (B) an oxo group, or
- 10 (C) R^{34} , OR^{34} , NHR^{34} , COR^{34} , $CONHR^{34}$, $COOR^{34}$, SO_2R^{34} , or SR^{34}

wherein R^{34} is defined as:

- 15 (i) a hydrogen atom,
- (ii) branched or unbranched alkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, which alkyl or cycloalkyl group may be mono- or polysubstituted with:
- 20 (a) oxo,
- (b) phenyl,
 wherein one or more hydrogen atoms of said phenyl group
25 may be optionally and independently replaced with:
 - (1) alkyl of 1 to 3 carbon atoms,
 - (2) -COOH,
 - 30 (3) -SO₂OH,

- 5
- 10
- 15
- 20
- 25
- 30
- (4) --PO(OH)_2 ,
- (5) a group of the formula --COOR^{35} , wherein R^{35} is straight or branched alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,
- (6) a group of the formula $\text{--NR}^{36}\text{R}^{37}$, wherein R^{36} and R^{37} are each independently a hydrogen atom, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms or acyl of 1 to 7 carbon atoms, or wherein R^{36} and R^{37} constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom between them form a heterocyclic ring,
- (7) a group of the formula $\text{--CONR}^{38}\text{R}^{39}$, wherein R^{38} and R^{39} are each independently a hydrogen atom, alkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, or wherein R^{38} and R^{39} constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom between them form a heterocyclic ring,
- (8) a group of the formula --OR^{40} , wherein R^{40} is a hydrogen atom, or an alkyl or acyl group of 1 to 7 carbon atoms,
- (9) a group of the formula --SR^{41} , wherein R^{41} is a hydrogen atom, or an alkyl or acyl group of 1 to 7 carbon atoms,
- (10) cyano, or

(11) an amidino group of the formula



5 wherein R⁴², R⁴³ and R⁴⁴ are each, independently, a hydrogen atom or alkyl of 1 to 3 carbon atoms and
10 wherein two of R⁴², R⁴³ and R⁴⁴ may additionally constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom(s) between them form a heterocyclic ring.

(h) a group of the formula $-NR^{50}R^{51}$, wherein R⁵⁰ and R⁵¹ are each, independently,

5

(1) a hydrogen atom,

10

(2) alkyl or acyl of 1 to 7 carbon atoms or cycloalkyl of 3 to 7 carbon atoms,

15


(3) a group of the formula $-(CH_2)_tCOOH$, wherein t is 0, 1 or 2, or

(4) a group of the formula $-(CH_2)_uCOOR^{52}$, wherein u is 0, 1 or 2, wherein R⁵² is straight or branched alkyl of 1 to 6 carbon atoms,

20

or wherein R⁵⁰ and R⁵¹ constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom between them form a heterocyclic ring, or


(i) a quaternary group of the formula



25

wherein R⁵³, R⁵⁴ and R⁵⁵ are each, independently, a branched or unbranched alkyl group of 1 to 7 carbon atoms and Q⁻ is a chlorine, bromine or iodine counterion,


- (iii) a branched or unbranched carboxylic acid group of 2 to 6 carbon atoms,
- 5 (iv) a branched or unbranched phosphonic acid group of 2 to 6 carbon atoms,
- (v) a branched or unbranched sulfonic acid group of 2 to 6 carbon atoms,
- 10 (vi) an amidino group of the formula



wherein r is 2, 3, 4, 5 or 6, and

15 R⁵⁶, R⁵⁷ and R⁵⁸ are each, independently, a hydrogen atom or alkyl of 1 to 3 carbon atoms, and wherein two of R⁵⁶, R⁵⁷ and R⁵⁸ may additionally constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom(s) between them form a heterocyclic ring,

- 20 (vii) a guanidino group of the formula



wherein s is 2, 3, 4, 5 or 6, and

25 R⁵⁹, R⁶⁰, R⁶¹ and R⁶² are each, independently, a hydrogen atom or alkyl of 1 to 3 carbon atoms, and wherein two of R⁵⁹, R⁶⁰, R⁶¹ and R⁶² may additionally constitute a saturated hydrocarbon bridge

of 3 to 5 carbon atoms which together with the nitrogen atom(s) between them form a heterocyclic ring,

(viii) phenyl,

5

wherein one or more hydrogen atoms of said phenyl group may be optionally and independently replaced with:

(a) alkyl of 1 to 3 carbon atoms,

10

(b) -COOH,

(c) -SO₂OH,

15

(d) -PO(OH)₂,

(e) a group of the formula -COOR⁶³, wherein R⁶³ is straight or branched alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,

20


(f) a group of the formula -NR⁶⁴R⁶⁵, wherein R⁶⁴ and R⁶⁵ are each, independently, a hydrogen atom, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms or acyl of 1 to 7 carbon atoms, or wherein R⁶⁴ and R⁶⁵ constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom between them form a heterocyclic ring,

25

(g) a group of the formula -CONR⁶⁶R⁶⁷, wherein R⁶⁶ and R⁶⁷ are each, independently, a hydrogen atom, alkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, or wherein R⁶⁶ and R⁶⁷ constitute a saturated hydrocarbon

30

bridge of 3 to 5 carbon atoms which together with the nitrogen atom between them form a heterocyclic ring,



15 wherein R⁷⁰, R⁷¹ and R⁷² are each, independently, a hydrogen atom or alkyl of 1 to 3 carbon atoms, and wherein two of R⁷⁰, R⁷¹ and R⁷² may additionally constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom(s) between them form a heterocyclic ring;

20

with the proviso that R^1 and R^2 are in the trans configuration;

25 and pharmaceutically acceptable salts thereof.

More preferred are compounds of the formula I, wherein:

m is 0 or 1,

n is 0 or 1, and

5 m + n is equal to either 1 or 2;

Y is an oxygen atom;

Z is an oxygen atom;

10

R¹ is:

(A) a hydrogen atom,

15

(B) methyl, or

(C) a group of the formula -OR¹³, wherein R¹³ is a an alkyl or acyl group of 1 to 2 carbon atoms;

20

R² is:

phenyl,

25

wherein one or more of the hydrogen atoms of said phenyl group may be optionally and independently replaced with:

(i) R¹⁴, which is aryl selected from the class consisting of phenyl, 3-pyridyl, or 5-pyrimidinyl,

30

wherein one or more of the hydrogen atoms of said R¹⁴ aryl group may be optionally and independently replaced with:

- (a) methyl,
 - (b) cyano,
 - 5 (c) nitro, or
 - (d) halogen,
- (ii) methyl, which may be mono- or polysubstituted with fluorine atoms,
- 10 (iii) branched or unbranched alkyl of 2 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, which alkyl or cycloalkyl group may be mono- or polysubstituted with halogen or oxo,
- 15 (iv) a group of the formula $-COOR^{22}$, wherein R²² is straight or branched alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,
- 20 (v) a group of the formula $-CONR^{25}R^{26}$, wherein R²⁵ and R²⁶ are each, independently, a hydrogen atom, alkyl or fluoroalkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, or wherein R²⁵ and R²⁶ constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom between them form a heterocyclic ring,
- 25 (vi) a group of the formula $-COR^{27}$, wherein R²⁷ is a hydrogen atom, straight or branched alkyl of 1 to 5 carbon atoms, or cycloalkyl of 3 to 5 carbon atoms,
- 30

(vii) a group of the formula $-OR^{28}$, wherein R²⁸ is a hydrogen atom, an alkyl, fluoroalkyl or acyl group of 1 to 7 carbon atoms,

5 (viii) a group of the formula $-SR^{29}$, wherein R²⁹ is a hydrogen atom, an alkyl, fluoroalkyl or acyl group of 1 to 7 carbon atoms,

10 (ix) cyano,

(x) nitro, or

(xi) halogen,

15

R³ is:

(A) a hydrogen atom,

20 (B) methyl, or

(C) a group of the formula $-OR^{33}$, wherein R³³ is a hydrogen atom methyl;

R⁴ is Cl or trifluoromethyl;

25

X is =N- or =CR⁵-,

wherein R⁵ is a hydrogen, fluorine, chlorine, bromine or iodine atom, methyl or trifluoromethyl;

30 R⁶ is a hydrogen, fluorine, chlorine, bromine or iodine atom, methyl, cyano, nitro or trifluoromethyl, with the condition that when X is N or =CH-, R⁶ is chlorine or trifluoromethyl;

R⁷, R⁸ and R⁹ are each, independently:

(A) a hydrogen atom,

5

(B) an oxo group, or

(C) R³⁴, OR³⁴, NHR³⁴, COR³⁴, CONHR³⁴, COOR³⁴, SO₂R³⁴, or SR³⁴

10 wherein R³⁴ is defined as:

(i) a hydrogen atom,

15 (ii) branched or unbranched alkyl of 1 to 6 carbon atoms or cycloalkyl
of 3 to 6 carbon atoms, which alkyl or cycloalkyl group may be
mono- or polysubstituted with:

(a) oxo,

20 (b) phenyl,

wherein one or more hydrogen atoms of said phenyl group
may be optionally and independently replaced with:

(1) alkyl of 1 to 3 carbon atoms,

25


(2) -COOH,

(3) -SO₂OH,

30

(4) -PO(OH)₂,

- (5) a group of the formula $-COOR^{35}$, wherein R³⁵ is straight or branched alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,
- 5 (6) a group of the formula $-NR^{36}R^{37}$, wherein R³⁶ and R³⁷ are each independently a hydrogen atom, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms or acyl of 1 to 7 carbon atoms, or wherein R³⁶ and R³⁷ constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom between them form a heterocyclic ring,
- 10 (7) a group of the formula $-CONR^{38}R^{39}$, wherein R³⁸ and R³⁹ are each independently a hydrogen atom, alkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, or wherein R³⁸ and R³⁹ constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom between them form a heterocyclic ring,
- 15 (8) a group of the formula $-OR^{40}$, wherein R⁴⁰ is a hydrogen atom, or an alkyl or acyl group of 1 to 7 carbon atoms,
- 20 (9) a group of the formula $-SR^{41}$, wherein R⁴¹ is a hydrogen atom, or an alkyl or acyl group of 1 to 7 carbon atoms,
- 25 (10) cyano, or
- 30 (11) an amidino group of the formula



wherein R⁴², R⁴³ and R⁴⁴ are each, independently, a hydrogen atom or alkyl of 1 to 3 carbon atoms and wherein two of R⁴², R⁴³ and R⁴⁴ may additionally constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom(s) between them form a heterocyclic ring,

5

10

15

20

25

- (c) a group of the formula -COOR⁴⁵, wherein R⁴⁵ is straight or branched alkyl of 1 to 7 carbon atoms or cycloalkyl of 3 to 6 carbon atoms,
- (d) cyano,
- (e) a group of the formula -CONR⁴⁶R⁴⁷, wherein R⁴⁶ and R⁴⁷ are each, independently, a hydrogen atom, alkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, or wherein R⁴⁶ and R⁴⁷ constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom between them form a heterocyclic ring,
- (f) a group of the formula -OR⁴⁸, wherein R⁴⁸ is a hydrogen atom, or an alkyl or acyl group of 1 to 7 carbon atoms,
- (g) a group of the formula -SR⁴⁹, wherein R⁴⁹ is a hydrogen atom, or an alkyl or acyl group of 1 to 7 carbon atoms,
- (h) a group of the formula -NR⁵⁰R⁵¹, wherein R⁵⁰ and R⁵¹ are each, independently,

(1) a hydrogen atom,


5 (2) alkyl or acyl of 1 to 7 carbon atoms or cycloalkyl of 3 to 7 carbon atoms,

(3) a group of the formula $-(\text{CH}_2)_t\text{COOH}$, wherein t is 0, 1 or 2, or

10 (4) a group of the formula $-(\text{CH}_2)_u\text{COOR}^{52}$, wherein u is 0, 1 or 2, wherein R⁵² is straight or branched alkyl of 1 to 6 carbon atoms,

15 or wherein R⁵⁰ and R⁵¹ constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom between them form a heterocyclic ring, or

(i) a quaternary group of the formula



20

wherein R⁵³, R⁵⁴ and R⁵⁵ are each, independently, a branched or unbranched alkyl group of 1 to 7 carbon atoms and Q⁻ is a chlorine, bromine or iodine counterion,

25


(iii) a branched or unbranched carboxylic acid group of 2 to 6 carbon atoms,

(iv) a branched or unbranched phosphonic acid group of 2 to 6 carbon atoms,

5

(v) a branched or unbranched sulfonic acid group of 2 to 6 carbon atoms,

(vi) an amidino group of the formula




10 wherein r is 2, 3, 4, 5 or 6, and

R⁵⁶, R⁵⁷ and R⁵⁸ are each, independently, a hydrogen atom or alkyl of 1 to 3 carbon atoms, and wherein two of R⁵⁶, R⁵⁷ and R⁵⁸ may additionally constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom(s) between them form a heterocyclic ring,

15

(vii) a guanidino group of the formula



20 wherein s is 2, 3, 4, 5 or 6, and

25

R⁵⁹, R⁶⁰, R⁶¹ and R⁶² are each, independently, a hydrogen atom or alkyl of 1 to 3 carbon atoms, and wherein two of R⁵⁹, R⁶⁰, R⁶¹ and R⁶² may additionally constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom(s) between them form a heterocyclic ring,

(viii) phenyl,

wherein one or more hydrogen atoms of said phenyl group may be optionally and independently replaced with:

5

(a) alkyl of 1 to 3 carbon atoms,

(b) -COOH,

10

(c) -SO₂OH,

(d) -PO(OH)₂,

15

(e) a group of the formula -COOR⁶³, wherein R⁶³ is straight or branched alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,

20

(f) a group of the formula -NR⁶⁴R⁶⁵, wherein R⁶⁴ and R⁶⁵ are each, independently, a hydrogen atom, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms or acyl of 1 to 7 carbon atoms, or wherein R⁶⁴ and R⁶⁵ constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom between them form a heterocyclic ring,


25

30

(g) a group of the formula -CONR⁶⁶R⁶⁷, wherein R⁶⁶ and R⁶⁷ are each, independently, a hydrogen atom, alkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, or wherein R⁶⁶ and R⁶⁷ constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom between them form a heterocyclic ring,

- (h) a group of the formula $-OR^{68}$, wherein R⁶⁸ is a hydrogen atom, or an alkyl or acyl group of 1 to 7 carbon atoms,
- 5 (i) a group of the formula $-SR^{69}$, wherein R⁶⁹ is a hydrogen atom, or an alkyl or acyl group of 1 to 7 carbon atoms,
- (j) cyano,
- (k) or, an amidino group of the formula

10



15

wherein R⁷⁰, R⁷¹ and R⁷² are each, independently, a hydrogen atom or alkyl of 1 to 3 carbon atoms, and wherein two of R⁷⁰, R⁷¹ and R⁷² may additionally constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom(s) between them form a heterocyclic ring;

20 with the proviso that R¹ and R² are in the trans configuration;

and pharmaceutically acceptable salts thereof.

25 Even more preferred are compounds of the formula I, wherein:

m is 0 or 1,

n is 0 or 1, and

m + n is equal to either 1 or 2;

Y is an oxygen atom;

5

Z is an oxygen atom;

R¹ is:

10

(A) a hydrogen atom, or

(B) methyl;

15 R² is:

phenyl,

wherein one or more of the hydrogen atoms of said phenyl group may be optionally and independently replaced with:

20

(i) R¹⁴, which is aryl selected from the class consisting of phenyl, 3-pyridyl, or 5-pyrimidinyl,

25

wherein one or more of the hydrogen atoms of said R¹⁴ aryl group may be optionally and independently replaced with:

(a) methyl,

(b) cyano,

30

(c) nitro, or

(d) halogen,

(ii) cyano,

5 (iii) nitro, or

(iv) halogen;

R^3 is a hydrogen atom;

10

R^4 is Cl;

X is =CH-;

15 R^6 is Cl;

R^7 , R^8 and R^9 are each, independently:

(A) a hydrogen atom,

20

(B) an oxo group, or

(C) R^{34} or OR^{34} ,


25 wherein R^{34} is defined as:

(i) a hydrogen atom,

30

(ii) branched or unbranched alkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, which alkyl or cycloalkyl group may be mono- or polysubstituted with:


- (a) oxo,
- (b) phenyl,
wherein one or more hydrogen atoms of said phenyl group
may be optionally and independently replaced with:
- (1) alkyl of 1 to 3 carbon atoms,
- (2) -COOH,
- (3) a group of the formula $-NR^{36}R^{37}$, wherein R³⁶ and R³⁷ are each independently a hydrogen atom, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms or acyl of 1 to 7 carbon atoms, or wherein R³⁶ and R³⁷ constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom between them form a heterocyclic ring,
- (4) a group of the formula $-OR^{40}$, wherein R⁴⁰ is a hydrogen atom, or an alkyl or acyl group of 1 to 7 carbon atoms, or
- (5) an amidino group of the formula



wherein R⁴², R⁴³ and R⁴⁴ are each, independently, a hydrogen atom or alkyl of 1 to 3 carbon atoms and wherein two of R⁴², R⁴³ and R⁴⁴ may additionally constitute a saturated hydrocarbon bridge of 3 to 5

carbon atoms which together with the nitrogen atom(s) between them form a heterocyclic ring,

- (c) a group of the formula $-OR^{48}$, wherein R^{48} is a hydrogen atom, or an alkyl or acyl group of 1 to 7 carbon atoms,
- (d) a group of the formula $-NR^{50}R^{51}$, wherein R^{50} and R^{51} are each, independently,
 - (1) a hydrogen atom,
 - (2) alkyl or acyl of 1 to 7 carbon atoms or cycloalkyl of 3 to 7 carbon atoms, or
 - (3) a group of the formula $-(CH_2)_tCOOH$, wherein t is 0, 1 or 2,
or wherein R^{50} and R^{51} constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom between them form a heterocyclic ring, or
- (iii) a branched or unbranched carboxylic acid group of 2 to 6 carbon atoms,
- (iv) an amidino group of the formula



wherein r is 2, 3, 4, 5 or 6, and


R⁵⁶, R⁵⁷ and R⁵⁸ are each, independently, a hydrogen atom or alkyl of 1 to 3 carbon atoms, and wherein two of R⁵⁶, R⁵⁷ and R⁵⁸ may additionally constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom(s) between them form a heterocyclic ring,

5

(v) phenyl,

10 wherein one or more hydrogen atoms of said phenyl group may be optionally and independently replaced with:

- (a) alkyl of 1 to 3 carbon atoms,
- 15 (b) -COOH,
- (c) a group of the formula -NR⁶⁴R⁶⁵, wherein R⁶⁴ and R⁶⁵ are each, independently, a hydrogen atom, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms or acyl of 1 to 7 carbon atoms, or wherein R⁶⁴ and R⁶⁵ constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom between them form a heterocyclic ring,
- 20 (d) a group of the formula -OR⁶⁸, wherein R⁶⁸ is a hydrogen atom, or an alkyl or acyl group of 1 to 7 carbon atoms,
- (e) or, an amidino group of the formula



wherein R⁷⁰, R⁷¹ and R⁷² are each, independently, a hydrogen atom or alkyl of 1 to 3 carbon atoms, and wherein
5 two of R⁷⁰, R⁷¹ and R⁷² may additionally constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom(s) between them form a heterocyclic ring;

10 with the proviso that R¹ and R² are in the trans configuration;

and pharmaceutically acceptable salts thereof.

15 Further preferred are compounds of the formula I, wherein:

m is 0 ;

n is 1;

20

Y is an oxygen atom;

Z is an oxygen atom;

25 R¹ is:

(A) a hydrogen atom, or

(B) methyl;

R² is:

phenyl,

5 wherein one or more of the hydrogen atoms of said phenyl group may be optionally and independently replaced with:

(i) R¹⁴, which is aryl selected from the class consisting of phenyl, 3-pyridyl, or 5-pyrimidinyl,

10

(ii) cyano,

(iii) nitro, or

15

(iv) halogen;

R³ is a hydrogen atom;

20 R⁴ is Cl;

X is =CH-;

R⁶ is Cl;

25

R⁷, R⁸ and R⁹ are each, independently:

(A) a hydrogen atom,

30 (B) an oxo group, or

(C) R³⁴ or OR³⁴,

wherein R³⁴ is defined as:

(i) a hydrogen atom,

5

(ii) branched or unbranched alkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, which alkyl or cycloalkyl group may be mono- or polysubstituted with a group of the formula -OR⁴⁸, wherein R⁴⁸ is a hydrogen atom, or an alkyl of 1 to 7 carbon atoms;

10

with the proviso that R¹ and R² are in the trans configuration;

and pharmaceutically acceptable salts thereof.

15

and pharmaceutically acceptable salts thereof.

Especially preferred compounds include:

- 20 2-(3,5-Dichlorophenyl)-7-(R*)- phenyl-7a-(R*)-tetrahydropyrrolo[1,2-c]imidazole-1,3-dione;
2-(3,5-Dichlorophenyl)- 7a-(R*)-methyl-7-(R*)- phenyl-tetrahydropyrrolo[1,2-c]imidazole-1,3-dione;
2-(3,5-Dichlorophenyl)-2-(4-Bromophenyl)-2-(3,5-dichlorophenyl)-7a-(R*)-tetrahydropyrrolo[1,2-c]imidazole-1,3-dione;
25 2-(3,5-dichlorophenyl)-8a-(R*)-methyl-8-(R*)-phenyl-tetrahydroimidazo[1,5-b]pyridine-1,3-dione;
2-(3,5-dichlorophenyl)-8a-(S*)-methoxy-8-(R*)-phenyl-tetrahydroimidazo[1,5-b]pyridine-1,3-dione;
30 7-(R*)-(4-Bromophenyl)-2-(3,5-dichlorophenyl)-7a-(R*)-methyl-tetrahydropyrrolo[1,2-c]imidazole-1,3-dione;
2-(3,5-dichlorophenyl)- 7-(R*)-[4-(3-pyridyl)phenyl]-7a-(R*)methyl-tetrahydropyrrolo[1,2-c]imidazole-1,3-dione;

7-(*R*⁴)-(4-Bromophenyl)-2-(3,5-dichlorophenyl)-6-(*S*⁵)-hydroxy-7a-(*R*⁴)-tetrahydropyrrolo[1,2-*c*]imidazole-1,3-dione;

7-(*R*⁴)-(4-Bromophenyl)-2-(3,5-dichlorophenyl)-7a-(*R*⁴)-allyl-tetrahydropyrrolo[1,2-*c*]imidazole-1,3-dione; and,


5 7-(*R*⁴)-(4-Bromophenyl)-2-(3,5-dichlorophenyl)-5-(*S*⁵)-hydroxy-7a-(*R*⁴)-methyl-tetrahydropyrrolo[1,2-*c*]imidazole-1,3-dione.

and pharmaceutically acceptable salts thereof.

10

In the names of the above-mentioned preferred compounds, the * denotes relative stereochemistry, not absolute stereochemistry.

15 It will be appreciated that the compounds of formula I have at least one chiral center.
Ultimately preferred are those compounds of formula I with the absolute stereochemistry
depicted below in formula Ia.




20

Synthesis of the Compounds of the Invention

The starting amino acids and their derivatives necessary for the synthesis of the compounds of the examples are either commercially available or are produced by obvious modifications of known literature. In particular, the method of Chung *et al.*, *J. Org. Chem.* 1990, 55, 270 – 275 teaches the synthesis and resolution of 3-substituted proline derivatives. When not obvious, the synthesis of the starting material is described. General

methods for the synthesis of compounds of the invention are described below and illustrated in Scheme I.

Scheme I



5

General Method A. Starting with an amino acid and a phenylisocyanate. Cyclization with acid.

- An appropriate amino acid is dissolved in aqueous base (such as, for example, NaOH,
 10 KOH, Na₂CO₃, NaHCO₃, K₂CO₃ or KHCO₃) and warmed to between about 20 and 90 °C. An appropriate isocyanate is added to this mixture and the resulting solution was stirred until the reaction essentially reaches completion. Upon cooling, the mixture is acidified and the resulting ureidoacetic acid is isolated by filtration or by extraction into organic solvent. Removal of solvent produces an intermediate which is cyclized by
 15 heating in the presence of a catalytic amount of acid (such as, for example, sulfuric acid, methanesulfonic acid, benzenesulfonic acid or hydrochloric acid) in an organic or aqueous solvent, to produce the desired hydantoin. Workup consists of collection of the desired

product by filtration and purification by, for example, silica gel chromatography or recrystallization.

5 **General Method B. Starting with an amino acid and a phenylisocyanate. Cyclization with EDC.**

An appropriate amino acid is dissolved in aqueous base (such as, for example, NaOH, KOH, Na₂CO₃, NaHCO₃, K₂CO₃ or KHCO₃) and warmed to between about 20 and 90 °C. An appropriate isocyanate is added to this mixture and the resulting solution is stirred 10 until the reaction essentially reaches completion. Upon cooling, the mixture is acidified and the resulting ureidoacetic acid is isolated by filtration or extraction into organic solvent. Removal of solvent produces the intermediate ureidoacetic acid which is then cyclized to the desired product in organic solvent (such as, for example, DMF, NMP, or THF) using any of a number of dehydrating agents (such as, for example, 15 dicyclohexylcarbodiimide (DCC) or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide HCl (EDC)) in the presence of an activating agent (such as 1-hydroxybenzotriazole hydrate (HOBT)) and a non-nucleophilic base (such as, for example, triethylamine or *N,N*-diisopropylethylamine). Work up consists of extraction into an organic solvent followed by purification via, for example, silica gel chromatography or recrystallization.

20

General Method C. Starting with an amino ester or a hydroxy ester and a phenylisocyanate. Cyclization with base or acid.

An appropriate amino ester or hydroxy ester and an appropriate isocyanate are dissolved in an organic solvent (such as, for example, DMF, THF or DMSO) in the presence of a base 25 (such as, for example, NaOH, KOH, Na₂CO₃, NaHCO₃, K₂CO₃ or KHCO₃) and warmed to between about room temperature and 60 °C. After approximately 1 h, the temperature of the reaction mixture is raised to between about 50 and 100 °C until the reaction appears complete. The solution is then cooled and diluted with an organic solvent (such as, for example, EtOAc or CH₂Cl₂). The organic phase is washed sequentially with dilute 30 aqueous acid (e.g. 1 N HCl) and water, dried (e.g. over MgSO₄) and concentrated. The desired product is purified, for example by silica gel chromatography or by recrystallization. (Alternatively the ureidoacetic ester can be cyclized to the product by


heating to between about 50 and 100 °C in the presence of an acid such as, for example, aqueous HCl until the reaction appears complete).

While the above general syntheses are illustrative of examples where X = Z = O, and R² = H, the preparation of other compounds of the invention will be apparent to those skilled in the art, e.g. use of an isothiocyanate in place of an isocyanate will provide compounds where X = S. Examples where R³ is an alkyl group can be prepared by alkylation of a compound where R² = H, as is described below in Examples 2 and 5.

10 Synthesis of Specific Compounds of the Examples.

Example 1.

2-(3,5-Dichlorophenyl)-7-(R*)-phenyl-7a-(R*)-tetrahydropyrrolo[1,2-c]imidazole-1,3-dione




15 Intermediate A (2.4 g, 9.2 mmol), synthesized by the method of Chung *et al.*, *J. Org. Chem.* 1990, 55, 270 – 275, was heated to reflux in 25 mL of 6 N HCl for 14 h. The solvents were removed by rotary evaporation to give the HCl salt of the amino acid B, after

recrystallization from EtOH/Et₂O (1.53 g, 72%). Intermediate **B** (1.13 g, 9.9 mmol) was then dissolved in 20 mL of water containing two equivalents of NaOH and then treated with 3,5-dichlorophenylisocyanate at 65 °C. After 1 h the mixture was cooled and filtered through a 0.45 µm filter. The water filtrate was acidified with concentrated HCl until a precipitate formed. The precipitate was isolated by filtration and dried which provided 960 mg (51%) of intermediate **C**. Intermediate **C** (408 mg, 1.07 mmol) was mixed at room temperature with EDC (206.2 mg, 1.07 mmol) and HOBT (145 mg, 1.07 mmol) in 20 mL of DMF for 1 h. *N,N*-diisopropylethylamine (278 mg, 2.15 mmol) was then added and the mixture was stirred for 18 h. The solution was then diluted with water and extracted three times into CH₂Cl₂. The organic layer was washed three times with water to remove residual DMF, dried over MgSO₄ and purified by silica gel chromatography (3:1 Hexanes:EtOAc) to yield 160 mg (41%) of the title compound (**1**). Mp 158 – 159 °C.

15 Example 2.

2-(3,5-Dichlorophenyl)- 7a-(R*)-methyl-7-(R*)- phenyl-tetrahydropyrrolo[1,2-c]imidazole-1,3-dione




Intermediate **D** (1.0 g, 4.3 mmol), synthesized by the method of Chung *et al.*, *J. Org. Chem.* 1990, 55, 270 – 275, was heated to reflux in 10 mL of AcOH and 10 mL of concentrated HCl for 6 h. The solvents were removed by rotary evaporation to give 0.98 g of a salt the amino acid **E** (note: this intermediate is commercially available as a single enantiomer). Intermediate **E** was then dissolved in 14.3 mL of water containing two equivalents of NaOH and then treated with 3,5-dichlorophenylisocyanate at 50 °C. After 2 h the mixture was cooled and treated with concentrated HCl until a precipitate formed. The precipitate was isolated by filtration and dried which provided 280 mg (17%) of intermediate **F** which was cyclized by heating at 90 °C in 5 mL of 6 N HCl for 3 days. The solid was then extracted into CH₂Cl₂ and purified by silica gel chromatography (3:1 Hexanes:EtOAc) to yield 220 mg (86%) of intermediate **G**. Mp 113 – 114 °C.

Intermediate **G** (90.3 mg, 0.25 mmol) was dissolved in 3 mL of THF and treated with 0.25 mL (0.25 mmol) of a 1 M solution of LDA in hexanes at –78 °C. After stirring for 15 min, the mixture was warmed to 0 °C and treated with 0.015 mL (0.25 mmol) of MeI. The solution was allowed to stir at room temperature for 3 h, at which point it was quenched with water, and the organic materials extracted into EtOAc. The EtOAc layers were

combined, dried over MgSO₄ and concentrated and the desired product was purified by silica gel chromatography using 4:1 Hexanes: EtOAc as the eluant. This produced 48 mg (53%) of the title compound **2**, Mp: 133-5 °C.

5 **Example 3.**

7-(R^{*})-(4-Bromophenyl)-2-(3,5-dichlorophenyl)-7a-(R^{*})-tetrahydropyrrolo[1,2-c]imidazole-1,3-dione




- 10 Intermediate **H** was prepared from 4-bromobenzaldehyde via the method reported by Rissanen (*Acta Chem. Scan.* 1989, 43, 787-792) for related compounds. It was converted to intermediate **I** via the method of Chung *et al.*, *J. Org. Chem.* 1990, 55, 270 – 275, and then to a diastereomeric mixture of the compounds of Example 3 and **K** using the technique reported above for the synthesis of the compound of Example 1 (via intermediate **J**). The two diastereomers were separated by silica gel chromatography (3:1 hexanes:EtOAc giving **K**, mp: 149 – 150 °C, and the compound of Example 3, mp: 185 – 6 °C.
- 15

Examples 4 and 5.

2-(3,5-dichlorophenyl)-8a-(R*)-methyl-8-(R*)-phenyl-tetrahydroimidazo[1,5-*b*]pyridine-1,3-dione and 2-(3,5-dichlorophenyl)-8a-(S*)-methoxy-8-(R*)-phenyl-

5 tetrahydroimidazo[1,5-*b*]pyridine-1,3-dione, respectively



The procedure for the synthesis of intermediate U can be considered a general procedure for the synthesis of 3-arylpipecolic acid derivatives.

To a solution of LDA (70 mmol) in THF (150 mL) was added a solution of ester L (10.0 g, 61 mmol) in THF (50 mL) at -78 °C under a nitrogen atmosphere. The mixture was stirred at -78 °C for 30 min before allyl bromide (5.8 mL, 67 mmol) was added. The mixture was stirred at -78 °C for 30 min and then room temperature for 2 h. Saturated NH₄Cl (100 mL) was added (with ice bath cooling) and the mixture was extracted into EtOAc, which was dried with Na₂SO₄ and concentrated. The residue was purified by 10 silica gel chromatography to give compound M (12.0 g, 96%).

To a solution of ester M (5.0 g, 24.5 mmol) in THF (100 mL) cooled at -78 °C was added DIBAL (1 M in toluene, 61 mL, 61 mmol) dropwise. The mixture was stirred at -78 °C for 30 min then room temperature for 10 h. The reaction was quenched with saturated 15 potassium-sodium tartrate solution at 0 °C. The mixture was extracted with EtOAc, dried (Na₂SO₄) and concentrated. The residue was purified by silica gel chromatography to give alcohol N (3.17 g, 80%).

A solution of the alcohol N (3.17 g, 20 mmol) in DMF (10 mL) was added to a suspension 20 of NaH (0.94 g, 60%, 24 mmol) in DMF (50 mL) at 0 °C under argon. The mixture was stirred at 0 °C for 30 m, then at room temperature for 1 h and then re-cooled to 0 °C. Benzyl bromide (2.6 mL, 21 mmol) was added followed by Bu₄NI (150 mg, 0.4 mmol). The mixture was stirred at 0 °C for 30 min and then at room temperature for 6 h. The 25 reaction was quenched at 0 °C with 1 N HCl (100 mL). The mixture was extracted with EtOAc and washed with a solution of saturated NaCl. Silica gel chromatography gave the benzyl ether O (4.3 g, 87%).

To a solution of intermediate O (4.28 g, 17 mmol) and Wilkinson's catalyst (320 mg, 0.35 mmol) in THF (100 mL) cooled to 0 °C was added catecholborane (1.0 M in THF, 30 mL, 30 30 mmol) dropwise under argon. The mixture was stirred at room temperature overnight. More reagents (10 mL of catecholborane, 10 mmol; and 200 mg of Wilkinson's catalyst, 0.21 mmol) were added and the mixture was stirred for additional 5 h. The mixture was

cooled to 0 °C. NaOH (6 M, 25 mL, 150 mmol) was added followed by H₂O₂ (30%, 22 mL, 0.19 mmol). The mixture was stirred overnight during which time it was while allowed to warm to room temperature. The mixture was extracted with ether, and the organic layer washed with saturated NaCl, dried and concentrated. The residue was
5 purified by silica gel chromatography to give alcohol P (3.0 g, 65%).

- To a solution of the alcohol P (3.14 g, 11.6 mmol) and Et₃N (1.1 mL, 17.4 mmol) in CH₂Cl₂ (100 mL) cooled at 0 °C was added slowly mesyl chloride (1.1 mL, 14.2 mmol) under argon. The mixture was stirred for 30 min at 0 °C before water (100 mL) was added.
10 The mixture was extracted with CH₂Cl₂ (2 x 100 mL). The organic layer was washed with water (200 mL), dried with Na₂SO₄ and concentrated. The crude material was dissolved in DMF (50 mL) and to the solution was added NaN₃ (4 g, 62 mmol). The mixture was stirred at room temperature overnight and concentrated using high vacuum. The residue was redissolved in EtOAc (250 mL), washed with water (2 x 100 mL) and
15 concentrated to give the azide Q (3.4 g, 99%).

A mixture of the azide Q (3.4g, 11.5 mmol), Boc₂O (3.1 g, 13.8 mmol), 10% Pd/C (0.5 g), EtOH (5 mL), AcOH (5 mL) and EtOAc (100 mL) was shaken in a Parr shaker under H₂ (50 psi) overnight. The mixture was filtered through a plug of silica gel and concentrated
20 to give intermediate R (2.6 g, 91%).

To a solution of oxalyl chloride (0.67 mL, 7.68 mmol) in CH₂Cl₂ (30 mL) cooled to -78 °C was added a mixture of DMSO (1.00 mL, 14.0 mmol) and CH₂Cl₂ (1 mL) dropwise under argon. After 10 m, a solution of the alcohol R (1.07 g, 3.84 mmol) in CH₂Cl₂ (10 mL) was added, and the mixture was stirred at -78 °C for 15 min at which time Et₃N (3.2 mL, 22.96 mmol) was added. The mixture was stirred at -78 °C for 10 min and warmed to room temperature. Water (100 mL) was added and the mixture was extracted with CH₂Cl₂. The organic layer was dried (Na₂SO₄) and concentrated and the residue was purified by silica gel chromatography to produce S as a mixture of two diastereomers (0.86 g, 81%).
30

To a solution of compound S (1.25 g, 4.51 mmol) in CH₂Cl₂ (10 mL) cooled to 0 °C was added TFA (4 mL). The solution was stirred at 0 °C for 10 min then at room temperature overnight. The mixture was concentrated and the residue was re-dissolved in a mixture of CH₃CN (30 mL) and H₂O (10 mL). To this solution was added KCN (1.5 g, 23 mmol).

- 5 The mixture was heated at 60 °C for 10 h, cooled to room temperature, and made basic with Na₂CO₃ (solid). The mixture was extracted with EtOAc, and the organic layer was washed with aqueous NaCl (sat.) and concentrated. The crude product was redissolved in CH₃CN and treated with Boc₂O (2.0 g, 8.9 mmol) and DMAP (150 mg). The mixture was stirred at overnight, concentrated and purified by silica gel chromatography to give 521 mg
10 of compound T (40%).

A suspension of the nitrile T (350 mg, 0.59 mmol) in 6 N HCl (10 mL) was refluxed under argon for 48 h. The mixture was concentrated to give the amino acid U (345 mg).

- 15 The crude material U from above was dissolved in H₂O (10 mL). The solution was made basic (pH ~ 8) with 2 N NaOH and heated to 60 °C. To this mixture was added dropwise a solution of 3,5-dichlorophenylisocyanate (330 mg, 1.68 mmol) in dioxane (4 mL). The mixture was heated for 1 h at 60 °C, cooled to 0 °C, acidified to pH~1, and extracted with EtOAc. The organic layer was concentrated and re-suspended in 6 N HCl and heated at 90
20 °C for an additional 4 h. The mixture was extracted with EtOAc, dried (Na₂SO₄), concentrated. Purification by silica gel chromatography give V (69 mg, 15%).

- To a solution of the compound V (20 mg, 0.053 mmol) in THF (2 mL) cooled to -78 °C under argon was added LiHMDS (0.107 mL, 1 M, 0.107 mmol). The mixture was stirred
25 for 30 min and treated with a mixture of HMPA (0.1 mL) and THF (0.1 mL). To the solution was next added MeI (0.020 mL, 0.320 mmol). The mixture was stirred at -78 °C for 30 min then at room temperature overnight. The reaction was quenched at 0 °C with 10% citric acid. The mixture was extracted with EtOAc, dried and concentrated. The residue was purified by preparative TLC (silica gel) to give compounds 4 (10 mg) and 5 (2
30 mg).


Table 1 illustrates additional compounds of the invention which were prepared by methods analogous to those described above.

Table 1

5

Example number	Structure
6	
7	
8	
9	

10

Description of Biological Properties

- 5 The biological properties of representative compounds of the formula I were investigated by way of the experimental protocol described below.

Assay to Determine Inhibition of LFA-1 Binding to ICAM-1

10 Purpose of Assay:

This assay protocol is designed to study the direct antagonism, by a test compound, of the interaction of the CAM, ICAM-1 with the Leukointegrin CD18/CD11a (LFA-1).

Description of Assay Protocol:

- 15 LFA-1 is immunopurified using the TS2/4 antibody from a 20 g pellet of human JY or SKW3 cells, utilizing a protocol previously described (Dustin, M. J.; *et al.*, *J. Immunol.* 1992, **148**, 2654-2660). The LFA-1 is purified from SKW3 lysates by immunoaffinity chromatography on TS2/4 LFA-1 mAb Sepharose and eluted at pH 11.5 in the presence of 2 mM MgCl₂ and 1% octylglucoside. After collection and neutralization of fractions from
20 the TS2/4 column, samples are pooled and precleared with Protein G agarose.

- A soluble form of ICAM-1 is constructed, expressed, purified and characterized as previously described (Marlin, S.; *et al.*, *Nature*, 1990, **344**, 70-72 and see Arruda, A.; *et al.*, *Antimicrob. Agents Chemother.* 1992, **36**, 1186-1192). Briefly, isoleucine 454 which is located at the putative boundary between domain 5 of the ectodomain and the transmembrane domain, is changed to a stop codon using standard oligonucleotide-directed mutagenesis. This construction yields a molecule identical with the first 453 amino acids

- of membrane bound ICAM-1. An expression vector is created with a hamster dihydrofolate reductase gene, a neomycin-resistance marker, and the coding region of the sICAM-1 construct described above, along with the promoter, splice signals, and polyadenylation signal of the SV40 early region. The recombinant plasmid is transfected
5 into CHO DUX cells using standard calcium phosphate methods. Cells are passaged in selective media (G418) and colonies secreting sICAM-1 are amplified using methotrexate. sICAM-1 is purified from serum-free media using traditional non-affinity chromatographic techniques, including ion exchange and size exclusion chromatography.
- 10 LFA-1 binding to ICAM-1 is monitored by first incubating sICAM-1 at 40 µg/mL in Dulbecco's phosphate buffered saline with calcium and magnesium, additional 2 mM MgCl₂ and 0.1 mM PMSF (Diluting Buffer) in a 96-well plate for 30 min at room temperature. Plates are then blocked by the addition of 2% (w/v) bovine serum albumin in Diluting Buffer for 37 °C for 1 h. Blocking solution is removed from wells, and test
15 compounds are diluted and then added followed by the addition of approximately 25 ng of immunoaffinity purified LFA-1. The LFA-1 is incubated in the presence of test compound and ICAM-1 at 37 °C for 1 h. Wells are washed 3 times with Diluting Buffer. The bound LFA-1 is detected by the addition of a polyclonal antibody directed against a peptide corresponding to the CD18 cytoplasmic tail in a 1:100 dilution with Diluting Buffer and
20 1% BSA and allowed to incubate for 45 min at 37 °C. Wells are washed 3 times with Diluting Buffer and the bound polyclonal antibody is detected by the addition of a 1:4000 dilution of horse radish peroxidase conjugated to goat immunoglobulin directed against rabbit immunoglobulin. This reagent is allowed to incubate for 20 min at 37 °C, wells are washed as above and the substrate for the horse radish peroxidase is added to each well to develop a quantitative colorimetric signal proportional to the amount of LFA-1 bound to
25 sICAM-1. Soluble ICAM-1 (60 µg/mL) is used as a positive control for inhibition of the LFA-1/ICAM-1 interaction. The lack of the addition of LFA-1 to the binding assay is used as a background control for all samples. A dose-response curve is obtained for all test compounds.
30 All compounds made in the above examples were tested in this assay and each found to have a K_d < 10 µM.

Description of Therapeutic Use

The novel small molecules of formula I provided by the invention inhibit the ICAM-1/LFA-1 dependent homotypic aggregation of human lymphocytes and human lymphocyte adherence to ICAM-1. These compounds have therapeutic utility in the modulation of immune cell activation/proliferation, *e.g.*, as competitive inhibitors of intercellular ligand/receptor binding reactions involving CAMs and Leukointegrins. To be more specific, the compounds of the invention may be used to treat certain inflammatory conditions, including conditions resulting from a response of the non-specific immune system in a mammal (*e.g.*, adult respiratory distress syndrome, shock, oxygen toxicity, multiple organ injury syndrome secondary to septicemia, multiple organ injury syndrome secondary to trauma, reperfusion injury of tissue due to cardiopulmonary bypass, myocardial infarction or use with thrombolysis agents, acute glomerulonephritis, vasculitis, reactive arthritis, dermatosis with acute inflammatory components, stroke, thermal injury, hemodialysis, leukapheresis, ulcerative colitis, necrotizing enterocolitis and granulocyte transfusion associated syndrome) and conditions resulting from a response of the specific immune system in a mammal (*e.g.*, psoriasis, organ/tissue transplant rejection, graft vs. host reactions and autoimmune diseases including Raynaud's syndrome, autoimmune thyroiditis, dermatitis, multiple sclerosis, rheumatoid arthritis, insulin-dependent diabetes mellitus, uveitis, inflammatory bowel disease including Crohn's disease and ulcerative colitis, and systemic lupus erythematosus). The compounds of the invention may also be used in treating asthma or as an adjunct to minimize toxicity with cytokine therapy in the treatment of cancers. In general these compounds may be employed in the treatment of those diseases currently treatable through steroid therapy.

Thus, another aspect of the invention is the provision of a method for the treatment or prophylaxis of the above-described conditions through the administration of therapeutic or prophylactic amounts of one or more compounds of the formula I.

30

In accordance with the method provided by the invention, the novel compounds of formula I may be administered for either a "prophylactic" or "therapeutic" purpose either alone or with other immunosuppressive or antiinflammatory agents. When provided

prophylactically, the immunosuppressive compound(s) are provided in advance of any inflammatory response or symptom (for example, prior to, at, or shortly after the time of an organ or tissue transplant but in advance of any symptoms of organ rejection). The prophylactic administration of a compound of the formula I serves to prevent or attenuate
5 any subsequent inflammatory response (such as, for example, rejection of a transplanted organ or tissue, etc.). The therapeutic administration of a compound of the formula I serves to attenuate any actual inflammation (such as, for example, the rejection of a transplanted organ or tissue). Thus, in accordance with the invention, a compound of the formula I can be administered either prior to the onset of inflammation (so as to suppress
10 an anticipated inflammation) or after the initiation of inflammation.

The novel compounds of the formula I may, in accordance with the invention, be administered in single or divided doses by the oral, parenteral or topical routes. A suitable oral dosage for a compound of formula I would be in the range of about 0.1 mg to 10 g per
15 day. In parenteral formulations, a suitable dosage unit may contain from 0.1 to 250 mg of said compounds, whereas for topical administration, formulations containing 0.01 to 1% active ingredient are preferred. It should be understood, however, that the dosage administration from patient to patient will vary and the dosage for any particular patient will depend upon the clinician's judgement, who will use as criteria for fixing a proper
20 dosage the size and condition of the patient as well as the patient's response to the drug.

When the compounds of the present invention are to be administered by the oral route, they may be administered as medicaments in the form of pharmaceutical preparations which contain them in association with a compatible pharmaceutical carrier material. Such
25 carrier material can be an inert organic or inorganic carrier material suitable for oral administration. Examples of such carrier materials are water, gelatin, talc, starch, magnesium stearate, gum arabic, vegetable oils, polyalkylene-glycols, petroleum jelly and the like.

30 The pharmaceutical preparations can be prepared in a conventional manner and finished dosage forms can be solid dosage forms, for example, tablets, dragees, capsules, and the like, or liquid dosage forms, for example solutions, suspensions, emulsions and the like. The pharmaceutical preparations may be subjected to conventional pharmaceutical

operations such as sterilization. Further, the pharmaceutical preparations may contain conventional adjuvants such as preservatives, stabilizers, emulsifiers, flavor-improvers, wetting agents, buffers, salts for varying the osmotic pressure and the like. Solid carrier material which can be used include, for example, starch, lactose, mannitol, methyl cellulose, microcrystalline cellulose, talc, silica, dibasic calcium phosphate, and high molecular weight polymers (such as polyethylene glycol).

- For parenteral use, a compound of formula I can be administered in an aqueous or non-aqueous solution, suspension or emulsion in a pharmaceutically acceptable oil or a mixture of liquids, which may contain bacteriostatic agents, antioxidants, preservatives, buffers or other solutes to render the solution isotonic with the blood, thickening agents, suspending agents or other pharmaceutically acceptable additives. Additives of this type include, for example, tartrate, citrate and acetate buffers, ethanol, propylene glycol, polyethylene glycol, complex formers (such as EDTA), antioxidants (such as sodium bisulfite, sodium metabisulfite, and ascorbic acid), high molecular weight polymers (such as liquid polyethylene oxides) for viscosity regulation and polyethylene derivatives of sorbitol anhydrides. Preservatives may also be added if necessary, such as benzoic acid, methyl or propyl paraben, benzalkonium chloride and other quaternary ammonium compounds.
- The compounds of this invention may also be administered as solutions for nasal application and may contain in addition to the compounds of this invention suitable buffers, tonicity adjusters, microbial preservatives, antioxidants and viscosity-increasing agents in an aqueous vehicle. Examples of agents used to increase viscosity are polyvinyl alcohol, cellulose derivatives, polyvinylpyrrolidone, polysorbates or glycerin. Microbial preservatives added may include benzalkonium chloride, thimerosal, chloro-butanol or phenylethyl alcohol.

Additionally, the compounds provided by the invention can be administered by suppository.

30

Formulations

Compounds of the formula I can be formulated for therapeutic administration in a number of ways. Descriptions of several exemplary formulations are given below.

Example A

5

Capsules or Tablets

Example A-1		Example A-2	
Ingredients	Quantity	Ingredients	Quantity
Compound of formula I	250 mg	Compound of formula I	50 mg
Starch	160 mg	Dicalcium Phosphate	160 mg
Microcrys. Cellulose	90 mg	Microcrys. Cellulose	90 mg
Sodium Starch Glycolate	10 mg	Stearic acid	5 mg
Magnesium Stearate	2 mg	Sodium Starch Glycolate	10 mg
Fumed colloidal silica	1 mg	Fumed colloidal silica	1 mg

The compound of formula I is blended into a powder mixture with the premixed excipient materials as identified above with the exception of the lubricant. The lubricant is then
10 blended in and the resulting blend compressed into tablets or filled into hard gelatin capsules.

Example B

15

Parenteral Solutions

Ingredients	Quantity
Compound of formula I	500 mg
PEG 400	40% by volume
Ethyl Alcohol	5% by volume
Saline	55% by volume

The excipient materials are mixed and then added to one of the compounds of formula I in such volume as is necessary for dissolution. Mixing is continued until the solution is clear.

The solution then filtered into the appropriate vials or ampoules and sterilized by autoclaving.

5 Example C


Suspension

Ingredients	Quantity
Compound of formula I	100 mg
Citric acid	1.92g
Benzalkonium chloride	0.025% by weight
EDTA	0.1 % by weight
Polyvinylalcohol	10% by weight
Water	q.s. to 100mL

10 The excipient materials are mixed with the water and thereafter one of the compounds of formula I is added and mixing is continued until the suspension is homogeneous. The suspension is then transferred into the appropriate vials or ampoules.

What is claimed is:

1. A compound of the formula I



5

wherein:

10 m is 0 or 1,

n is 0 or 1, and

m + n is equal to either 1 or 2;

15

Y is an oxygen or sulfur atom;

Z is an oxygen or sulfur atom;

20 R¹ is:

(A) a hydrogen atom, or

25 (B) branched or unbranched alkyl of 1 to 3 carbon atoms or cycloalkyl of 3 to 5 carbon atoms wherein said alkyl or cycloalkyl group may optionally be substituted with:

- (i) a group of the formula $-OR^{10}$, wherein R^{10} is an alkyl or acyl group of 1 to 2 carbon atoms,
- 5 (ii) a group of the formula $-NR^{11}R^{12}$, wherein R^{11} and R^{12} are each, independently, alkyl of 1 to 2 carbon atoms, or acyl of 1 to 2 carbon atoms, or
- (C) a group of the formula $-OR^{13}$, wherein R^{13} is a an alkyl or acyl group of 1 to 2 carbon atoms;

10

 R^2 is:

aryl selected from the class consisting of phenyl, 2-naphthyl, 2-, 3-, 5- or 6-indolyl, 2- or 3-thiophenyl, 2-, 3- or 4-pyridyl, 2-, 4- or 5-pyrimidinyl, 2- or 3-furyl, 1-, 2- or 3-pyrrolyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, 1-, 3-, 4- or 5-pyrazolyl, 3-, 4- or 5-isoxazolyl, 1-, 2-, 4- or 5-imidazolyl, 3-, 4- or 5-isothiazolyl, 4- or 5-oxadiazolyl, 1-, 4- or 5-triazolyl, 2-thiadiazolyl, 3- or 4-pyridazinyl, 2-pyrazinyl, 2-triazinyl, 2-, 3-, 6- or 7-indolyzinyl, 2-, 3-, 5- or 6-isoindolyl, 2-, 3-, 5- or 6-benzo[b]furanyl, 2-, 3-, 5- or 6-benzo[b]thiophenyl, 3-, 5- or 6-indazolyl, 2-, 5- or 6-benzthiazolyl, 2-, 5- or 6-benzimidazolyl, 2-, 3-, 6- or 7-quinolinyl, 3-, 6- or 7-isoquinolinyl, 2- or 8-purinyl, 2-, 3-, 7- or 8-quinolizinyl, 3-, 6- or 7-cinnolinyl, 6- or 7-phthalaninyl, 2-, 3-, 6- or 7-quinoxalinyl, 2-, 3-, 6- or 7-naphthyridinyl, 2-, 6- or 7-pteridinyl and 2-, 6- or 7-quinazolinyl,

15

20

25

wherein one or more of the hydrogen atoms of said aryl group may be optionally and independently replaced with:

30

- (i) R^{14} , which is aryl selected from the class consisting of phenyl, 2-naphthyl, 2-, 3-, 5- or 6-indolyl, 2- or 3-thiophenyl, 2-, 3- or 4-pyridyl, 2-, 4- or 5-pyrimidinyl, 2- or 3-furyl, 1-, 2- or 3-pyrrolyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, 1-, 3-, 4- or 5-pyrazolyl, 3-, 4- or 5-isoxazolyl, 1-, 2-, 4- or 5-imidazolyl, 3-, 4- or 5-isothiazolyl, 4- or 5-oxadiazolyl, 1-, 4- or 5-triazolyl, 2-thiadiazolyl, 3- or 4-pyridazinyl, 2-pyrazinyl, 2-triazinyl, 2-, 3-, 6- or 7-indolyzinyl, 2-, 3-, 5- or 6-isoindolyl, 2-, 3-, 5- or 6-benzo[b]furanyl, 2-, 3-, 5- or 6-benzo[b]thiophenyl, 3-, 5- or 6-indazolyl, 2-, 5- or 6-benzthiazolyl, 2-, 5- or 6-benzimidazolyl, 2-, 3-, 6- or 7-quinolinyl, 3-, 6- or 7-isoquinolinyl, 2- or 8-purinyl, 2-, 3-, 7- or 8-quinolizinyl, 3-, 6- or 7-cinnolinyl, 6- or 7-phthalaninyl, 2-, 3-, 6- or 7-quinoxalinyl, 2-, 3-, 6- or 7-naphthyridinyl, 2-, 6- or 7-pteridinyl and 2-, 6- or 7-quinazolinyl,

or 5-triazolyl, 2-thiadiazolyl, 3- or 4-pyridazinyl, 2-pyrazinyl, 2-triazinyl, 2-, 3-, 6- or 7-indolyzinyl, 2-, 3-, 5- or 6-isoindolyl, 2-, 3-, 5- or 6-benzo[b]furanyl, 2-, 3-, 5- or 6-benzo[b]thiophenyl, 3-, 5- or 6-indazolyl, 2-, 5- or 6-benzthiazolyl, 2-, 5- or 6-benzimidazolyl, 2-, 3-, 6- or 7-quinolinyl, 3-, 6- or 7-isoquinolinyl, 2- or 8-purinyl, 2-, 3-, 7- or 8-quinolizinyl, 3-, 6- or 7-cinnolinyl, 6- or 7-phthalaninyl, 2-, 3-, 6- or 7-quinoxalinyl, 2-, 3-, 6- or 7-naphthyridinyl, 2-, 6- or 7-pteridinyl and 2-, 6- or 7-quinazolinyl,

10

wherein one or more of the hydrogen atoms of said R¹⁴ aryl group may be optionally and independently replaced with:

15

(a) branched or unbranched alkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, which alkyl or cycloalkyl group may be mono- or polysubstituted with halogen or oxo,

20

(b) a group of the formula -COOR¹⁵, wherein R¹⁵ is straight or branched alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,

25

(c) a group of the formula -NR¹⁶R¹⁷, wherein R¹⁶ and R¹⁷ are each, independently, a hydrogen atom, alkyl or fluoroalkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms or acyl of 1 to 7 carbon atoms, or wherein R¹⁶ and R¹⁷ constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom between them form a heterocyclic ring,

30

- 5
- (d) a group of the formula $-\text{CONR}^{18}\text{R}^{19}$, wherein R^{18} and R^{19} are each independently a hydrogen atom, alkyl or fluoroalkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, or wherein R^{18} and R^{19} constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom between them form a heterocyclic ring,
- 10
- (e) a group of the formula $-\text{OR}^{20}$, wherein R^{20} is a hydrogen atom, or an alkyl, fluoroalkyl or acyl group of 1 to 7 carbon atoms,
- 15
- (f) a group of the formula $-\text{SR}^{21}$, wherein R^{21} is a hydrogen atom, or an alkyl, fluoroalkyl or acyl group of 1 to 7 carbon atoms,
- (g) cyano,
- 20
- (h) nitro,
- (i) halogen,
- 25
- (ii) methyl, which may be mono- or polysubstituted with fluorine atoms,
- (iii) branched or unbranched alkyl of 2 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, which alkyl or cycloalkyl group may be mono- or polysubstituted with halogen or oxo,
- 30
- (iv) a group of the formula $-\text{COOR}^{22}$, wherein R^{22} is straight or branched alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,

- 5
- (v) a group of the formula $-NR^{23}R^{24}$, wherein R²³ and R²⁴ are each, independently, a hydrogen atom, alkyl or fluoroalkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms or acyl of 1 to 7 carbon atoms, or wherein R²³ and R²⁴ constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom between them form a heterocyclic ring,
- 10
- (vi) a group of the formula $-CONR^{25}R^{26}$, wherein R²⁵ and R²⁶ are each, independently, a hydrogen atom, alkyl or fluoroalkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, or wherein R²⁵ and R²⁶ constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom between them form a heterocyclic ring,
- 15
- (vii) a group of the formula $-COR^{27}$, wherein R²⁷ is a hydrogen atom, straight or branched alkyl of 1 to 5 carbon atoms, or cycloalkyl of 3 to 5 carbon atoms,
- 20
- (viii) a group of the formula $-OR^{28}$, wherein R²⁸ is a hydrogen atom, an alkyl, fluoroalkyl or acyl group of 1 to 7 carbon atoms,
- 25
- (ix) a group of the formula $-SR^{29}$, wherein R²⁹ is a hydrogen atom, an alkyl, fluoroalkyl or acyl group of 1 to 7 carbon atoms,
- 30
- (x) cyano,
- (xi) nitro, or

(xii) halogen,

R³ is:

5

- (A) a hydrogen atom, or
- (B) branched or unbranched alkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms wherein said alkyl or cycloalkyl group may optionally be substituted with:
 - 10 (i) a group of the formula -OR³⁰, wherein R³⁰ is a hydrogen atom, or an alkyl or acyl group of 1 to 6 carbon atoms,
 - (ii) a group of the formula -NR³¹R³², wherein R³¹ and R³² are each, independently, a hydrogen atom, alkyl of 1 to 6 carbon atoms, or acyl of 1 to 6 carbon atoms,
- 15 (C) a group of the formula -OR³³, wherein R³³ is a hydrogen atom, or an alkyl or acyl group of 1 to 6 carbon atoms;

20

R⁴ is Cl or trifluoromethyl;

25 X is =N- or =CR⁵-,

wherein R⁵ is a hydrogen, fluorine, chlorine, bromine or iodine atom, methyl or trifluoromethyl;

30 R⁶ is a hydrogen, fluorine, chlorine, bromine or iodine atom, methyl, cyano, nitro or trifluoromethyl, with the condition that when X is N or =CH-, R⁶ is chlorine or trifluoromethyl;

R⁷, R⁸ and R⁹ are each, independently:

- 5 (A) a hydrogen atom,
 (B) an oxo group, or
 (C) R³⁴, OR³⁴, NHR³⁴, COR³⁴, CONHR³⁴, COOR³⁴, SO₂R³⁴, or SR³⁴

wherein R³⁴ is defined as:

- 10 (i) a hydrogen atom,
 (ii) branched or unbranched alkyl of 1 to 6 carbon atoms or cycloalkyl
 of 3 to 6 carbon atoms, which alkyl or cycloalkyl group may be
 mono- or polysubstituted with:
15 (a) halogen,
 (b) oxo,
 (c) aryl which is selected from the class consisting of phenyl,
 naphthyl, indolyl, thiophenyl, pyridyl, pyrimidinyl, furyl,
 pyrrolyl, oxazolyl, thiazolyl, pyrazolyl, isoxazolyl,
 imidazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl,
 pyridazinyl, pyrazinyl, triazinyl, indolizinyl, isoindolyl,
20 benzo[b]furanyl, benzo[b]thiophenyl, indazolyl,
 benzthiazolyl, benzimidazolyl, quinolinyl, isoquinolinyl,
 purinyl, quinolizinyl, cinnolinyl, pthalaninyl, quinoxalinyl,
 napthyridinyl, pteridinyl and quinazolinyl,
25
 wherein one or more hydrogen atoms of said aryl group may
 be optionally and independently replaced with:
 (1) alkyl of 1 to 3 carbon atoms,


- 5
- (2) -COOH,
- (3) -SO₂OH,
- 10 (4) -PO(OH)₂,
- (5) a group of the formula -COOR³⁵, wherein R³⁵ is straight or branched alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,
- 15 (6) a group of the formula -NR³⁶R³⁷, wherein R³⁶ and R³⁷ are each independently a hydrogen atom, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms or acyl of 1 to 7 carbon atoms, or wherein R³⁶ and R³⁷ constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom between them form a heterocyclic ring,
- 20 (7) a group of the formula -CONR³⁸R³⁹, wherein R³⁸ and R³⁹ are each independently a hydrogen atom, alkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, or wherein R³⁸ and R³⁹ constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom between them form a heterocyclic ring,
- 25 (8) a group of the formula -OR⁴⁰, wherein R⁴⁰ is a hydrogen atom, or an alkyl or acyl group of 1 to 7 carbon atoms,
- 30

(9) a group of the formula $-SR^{41}$, wherein R⁴¹ is a hydrogen atom, or an alkyl or acyl group of 1 to 7 carbon atoms,

5

(10) cyano, or

(11) an amidino group of the formula



10

wherein R⁴², R⁴³ and R⁴⁴ are each, independently, a hydrogen atom or alkyl of 1 to 3 carbon atoms and wherein two of R⁴², R⁴³ and R⁴⁴ may additionally constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom(s) between them form a heterocyclic ring,

15

20

(d) a group of the formula $-COOR^{45}$, wherein R⁴⁵ is straight or branched alkyl of 1 to 7 carbon atoms or cycloalkyl of 3 to 6 carbon atoms,

(e) cyano,

25

(f) a group of the formula $-CONR^{46}R^{47}$, wherein R⁴⁶ and R⁴⁷ are each, independently, a hydrogen atom, alkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, or wherein R⁴⁶ and R⁴⁷ constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom between them form a heterocyclic ring,

(g) a group of the formula $-OR^{48}$, wherein R⁴⁸ is a hydrogen atom, or an alkyl or acyl group of 1 to 7 carbon atoms,

5 (h) a group of the formula $-SR^{49}$, wherein R⁴⁹ is a hydrogen atom, or an alkyl or acyl group of 1 to 7 carbon atoms,

(i) a group of the formula $-NR^{50}R^{51}$, wherein R⁵⁰ and R⁵¹ are each, independently,

10 (1) a hydrogen atom,


(2) alkyl or acyl of 1 to 7 carbon atoms or cycloalkyl of 3 to 7 carbon atoms,

15 (3) a group of the formula $-(CH_2)_tCOOH$, wherein t is 0, 1 or 2, or

(4) a group of the formula $-(CH_2)_uCOOR^{52}$, wherein u is 0, 1 or 2, wherein R⁵² is straight or branched alkyl of 1 to 6 carbon atoms,

20
25 or wherein R⁵⁰ and R⁵¹ constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom between them form a heterocyclic ring, or

(j) a quaternary group of the formula



wherein R⁵³, R⁵⁴ and R⁵⁵ are each, independently, a branched or unbranched alkyl group of 1 to 7 carbon atoms and Q⁻ is a chlorine, bromine or iodine counterion,

5

(iii) a branched or unbranched carboxylic acid group of 2 to 6 carbon atoms,


10

(iv) a branched or unbranched phosphonic acid group of 2 to 6 carbon atoms,

15

(v) a branched or unbranched sulfonic acid group of 2 to 6 carbon atoms,

(vi) an amidino group of the formula




wherein r is 2, 3, 4, 5 or 6, and

20

R⁵⁶, R⁵⁷ and R⁵⁸ are each, independently, a hydrogen atom or alkyl of 1 to 3 carbon atoms, and wherein two of R⁵⁶, R⁵⁷ and R⁵⁸ may additionally constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom(s) between them form a heterocyclic ring,

25

(vii) a guanidino group of the formula



wherein s is 2, 3, 4, 5 or 6, and

5 R⁵⁹, R⁶⁰, R⁶¹ and R⁶² are each, independently, a hydrogen atom or alkyl of 1 to 3 carbon atoms, and wherein two of R⁵⁹, R⁶⁰, R⁶¹ and R⁶² may additionally constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom(s) between them form a heterocyclic ring,

- 10 (viii) aryl which is selected from the class consisting of phenyl, naphthyl, indolyl, thiophenyl, pyridyl, pyrimidinyl, furyl, pyrrolyl, oxazolyl, thiazolyl, pyrazolyl, isoxazolyl, imidazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyridazinyl, pyrazinyl, triazinyl, indolizinyl, isoindolyl, benzo[b]furanyl, benzo[b]thiophenyl, indazolyl, benzthiazolyl, benzimidazolyl, quinolinyl, isoquinolinyl, purinyl, quinolizinyl, cinnolinyl, phthalaninyl, quinoxalinyl, naphthyridinyl, pteridinyl and quinazolinyl,
- 15

wherein one or more hydrogen atoms of said aryl group may be optionally and independently replaced with:

20

(a) alkyl of 1 to 3 carbon atoms,

(b) -COOH,

25


(c) -SO₂OH,

(d) -PO(OH)₂,

30

(e) a group of the formula -COOR⁶³, wherein R⁶³ is straight or branched alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,

- (f) a group of the formula $-NR^{64}R^{65}$, wherein R⁶⁴ and R⁶⁵ are each, independently, a hydrogen atom, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms or acyl of 1 to 7 carbon atoms, or wherein R⁶⁴ and R⁶⁵ constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom between them form a heterocyclic ring,
- (g) a group of the formula $-CONR^{66}R^{67}$, wherein R⁶⁶ and R⁶⁷ are each, independently, a hydrogen atom, alkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, or wherein R⁶⁶ and R⁶⁷ constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom between them form a heterocyclic ring,
- (h) a group of the formula $-OR^{68}$, wherein R⁶⁸ is a hydrogen atom, or an alkyl or acyl group of 1 to 7 carbon atoms,
- (i) a group of the formula $-SR^{69}$, wherein R⁶⁹ is a hydrogen atom, or an alkyl or acyl group of 1 to 7 carbon atoms,
- (j) cyano,
- (k) or, an amidino group of the formula



wherein R⁷⁰, R⁷¹ and R⁷² are each, independently, a hydrogen atom or alkyl of 1 to 3 carbon atoms, and wherein

two of R⁷⁰, R⁷¹ and R⁷² may additionally constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom(s) between them form a heterocyclic ring;

5

with the proviso that R¹ and R² are in the trans configuration;

or a pharmaceutically acceptable salt thereof.

10

2. A compound of the formula I, in accordance with claim 1, wherein:

m is 0 or 1,

15 n is 0 or 1, and

m + n is equal to either 1 or 2;

Y is an oxygen or sulfur atom;

20

Z is an oxygen or sulfur atom;

R¹ is:

25 (A) a hydrogen atom, or

(B) branched or unbranched alkyl of 1 to 3 carbon atoms or cycloalkyl of 3 to 5 carbon atoms wherein said alkyl or cycloalkyl group may optionally be substituted with:

30

(i) a group of the formula -OR¹⁰, wherein R¹⁰ is an alkyl or acyl group of 1 to 2 carbon atoms,

(ii) a group of the formula $-NR^{11}R^{12}$, wherein R¹¹ and R¹² are each, independently, alkyl of 1 to 2 carbon atoms, or acyl of 1 to 2 carbon atoms, or

5 (C) a group of the formula $-OR^{13}$, wherein R¹³ is a an alkyl or acyl group of 1 to 2 carbon atoms;

R² is:

aryl selected from the class consisting of phenyl, 2-naphthyl, 2-, 3-, 5- or 6-indolyl,
10 2- or 3-thiophenyl, 2-, 3- or 4-pyridyl, 2-, 4- or 5-pyrimidinyl, 2- or 3-furyl, 1-, 2- or 3-pyrrolyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, 1-, 3-, 4- or 5-pyrazolyl, 3-, 4- or 5-isoxazolyl, 1-, 2-, 4- or 5-imidazolyl, 3-, 4- or 5-isothiazolyl, 4- or 5-oxadiazolyl, 1-, 4- or 5-triazolyl, 2-thiadiazolyl, 3- or 4-pyridazinyl, 2-pyrazinyl, 2-triazinyl, 2-, 3-, 6- or 7-indolyzinyl, 2-, 3-, 5- or 6-isoindolyl, 2-, 3-, 5- or 6-benzo[b]furanyl, 2-, 3-, 5- or 6-benzo[b]thiophenyl, 3-, 5- or 6-indazolyl, 2-, 5- or 6-benzthiazolyl, 2-, 5- or 6-benzimidazolyl, 2-, 3-, 6- or 7-quinolinyl, 3-, 6- or 7-isoquinolinyl, 2- or 8-purinyl, 2-, 3-, 7- or 8-quinolizinyl, 3-, 6- or 7-cinnolinyl, 6- or 7-phthalaninyl, 2-, 3-, 6- or 7-quinoxalinyl, 2-, 3-, 6- or 7-naphthyridinyl, 2-, 6- or 7-pteridinyl and 2-, 6- or 7-quinazolinyl,

20 25 wherein one or more of the hydrogen atoms of said aryl group may be optionally and independently replaced with:

(i) R¹⁴, which is aryl selected from the class consisting of phenyl, 2-naphthyl, 2-, 3-, 5- or 6-indolyl, 2- or 3-thiophenyl, 2-, 3- or 4-pyridyl, 2-, 4- or 5-pyrimidinyl, 2- or 3-furyl, 1-, 2- or 3-pyrrolyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, 1-, 3-, 4- or 5-pyrazolyl, 3-, 4- or 5-isoxazolyl, 1-, 2-, 4- or 5-imidazolyl, 3-, 4- or 5-isothiazolyl, 4- or 5-oxadiazolyl, 1-, 4- or 5-triazolyl, 2-thiadiazolyl, 3- or 4-pyridazinyl, 2-pyrazinyl, 2-triazinyl, 2-, 3-, 6- or 7-indolyzinyl, 2-, 3-, 5- or 6-isoindolyl, 2-, 3-, 5- or 6-benzo[b]furanyl, 2-, 3-, 5- or 6-benzo[b]thiophenyl, 3-, 5- or 6-indazolyl, 2-, 5- or 6-benzthiazolyl, 2-, 5- or 6-benzimidazolyl, 2-, 3-, 6- or 7-quinolinyl, 3-, 6- or 7-isoquinolinyl, 2- or 8-purinyl, 2-, 3-, 7- or 8-quinolizinyl, 3-, 6- or 7-cinnolinyl, 6- or 7-phthalaninyl, 2-, 3-, 6- or 7-quinoxalinyl, 2-, 3-, 6- or 7-naphthyridinyl, 2-, 6- or 7-pteridinyl and 2-, 6- or 7-quinazolinyl,

benzo[b]thiophenyl, 3-, 5- or 6-indazolyl, 2-, 5- or 6-benzthiazolyl, 2-, 5- or 6-benzimidazolyl, 2-, 3-, 6- or 7-quinolinyl, 3-, 6- or 7-isoquinolinyl, 2- or 8-purinyl, 2-, 3-, 7- or 8-quinolizinyl, 3-, 6- or 7-cinnolinyl, 6- or 7-phthalaninyl, 2-, 3-, 6- or 7-quinoxalinyl, 2-, 3-, 6- or 7-naphthyridinyl, 2-, 6- or 7-pteridinyl and 2-, 6- or 7-quinazolinyl,

wherein one or more of the hydrogen atoms of said R¹⁴ aryl group may be optionally and independently replaced with:

10

(a) branched or unbranched alkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, which alkyl or cycloalkyl group may be mono- or polysubstituted with halogen or oxo,

15

(b) a group of the formula -COOR¹⁵, wherein R¹⁵ is straight or branched alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,

20

(c) a group of the formula -NR¹⁶R¹⁷, wherein R¹⁶ and R¹⁷ are each, independently, a hydrogen atom, alkyl or fluoroalkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms or acyl of 1 to 7 carbon atoms, or wherein R¹⁶ and R¹⁷ constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom between them form a heterocyclic ring,

25

(d) a group of the formula -CONR¹⁸R¹⁹, wherein R¹⁸ and R¹⁹ are each independently a hydrogen atom, alkyl or fluoroalkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, or wherein R¹⁸

30

and R¹⁹ constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom between them form a heterocyclic ring,

5

(e) a group of the formula -OR²⁰, wherein R²⁰ is a hydrogen atom, or an alkyl, fluoroalkyl or acyl group of 1 to 7 carbon atoms,

10

(f) a group of the formula -SR²¹, wherein R²¹ is a hydrogen atom, or an alkyl, fluoroalkyl or acyl group of 1 to 7 carbon atoms,

15

(g) cyano,

20

(h) nitro,

(i) halogen,

25

(ii) methyl, which may be mono- or polysubstituted with fluorine atoms,

25

(iii) branched or unbranched alkyl of 2 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, which alkyl or cycloalkyl group may be mono- or polysubstituted with halogen or oxo,

30

(iv) a group of the formula -COOR²², wherein R²² is straight or branched alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,

(v) a group of the formula -NR²³R²⁴, wherein R²³ and R²⁴ are each, independently, a hydrogen atom, alkyl or fluoroalkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms or

acyl of 1 to 7 carbon atoms, or wherein R²³ and R²⁴ constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom between them form a heterocyclic ring,

5

- (vi) a group of the formula -CONR²⁵R²⁶, wherein R²⁵ and R²⁶ are each, independently, a hydrogen atom, alkyl or fluoroalkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, or wherein R²⁵ and R²⁶ constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom between them form a heterocyclic ring,
- 10
15
20
25
- (vii) a group of the formula -COR²⁷, wherein R²⁷ is a hydrogen atom, straight or branched alkyl of 1 to 5 carbon atoms, or cycloalkyl of 3 to 5 carbon atoms,
- (viii) a group of the formula -OR²⁸, wherein R²⁸ is a hydrogen atom, an alkyl, fluoroalkyl or acyl group of 1 to 7 carbon atoms,
- (ix) a group of the formula -SR²⁹, wherein R²⁹ is a hydrogen atom, an alkyl, fluoroalkyl or acyl group of 1 to 7 carbon atoms,
- (x) cyano,
- (xi) nitro, or
- 30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
105
110
115
120
125
130
135
140
145
150
155
160
165
170
175
180
185
190
195
200
205
210
215
220
225
230
235
240
245
250
255
260
265
270
275
280
285
290
295
300
305
310
315
320
325
330
335
340
345
350
355
360
365
370
375
380
385
390
395
400
405
410
415
420
425
430
435
440
445
450
455
460
465
470
475
480
485
490
495
500
505
510
515
520
525
530
535
540
545
550
555
560
565
570
575
580
585
590
595
600
605
610
615
620
625
630
635
640
645
650
655
660
665
670
675
680
685
690
695
700
705
710
715
720
725
730
735
740
745
750
755
760
765
770
775
780
785
790
795
800
805
810
815
820
825
830
835
840
845
850
855
860
865
870
875
880
885
890
895
900
905
910
915
920
925
930
935
940
945
950
955
960
965
970
975
980
985
990
995
1000
1005
1010
1015
1020
1025
1030
1035
1040
1045
1050
1055
1060
1065
1070
1075
1080
1085
1090
1095
1100
1105
1110
1115
1120
1125
1130
1135
1140
1145
1150
1155
1160
1165
1170
1175
1180
1185
1190
1195
1200
1205
1210
1215
1220
1225
1230
1235
1240
1245
1250
1255
1260
1265
1270
1275
1280
1285
1290
1295
1300
1305
1310
1315
1320
1325
1330
1335
1340
1345
1350
1355
1360
1365
1370
1375
1380
1385
1390
1395
1400
1405
1410
1415
1420
1425
1430
1435
1440
1445
1450
1455
1460
1465
1470
1475
1480
1485
1490
1495
1500
1505
1510
1515
1520
1525
1530
1535
1540
1545
1550
1555
1560
1565
1570
1575
1580
1585
1590
1595
1600
1605
1610
1615
1620
1625
1630
1635
1640
1645
1650
1655
1660
1665
1670
1675
1680
1685
1690
1695
1700
1705
1710
1715
1720
1725
1730
1735
1740
1745
1750
1755
1760
1765
1770
1775
1780
1785
1790
1795
1800
1805
1810
1815
1820
1825
1830
1835
1840
1845
1850
1855
1860
1865
1870
1875
1880
1885
1890
1895
1900
1905
1910
1915
1920
1925
1930
1935
1940
1945
1950
1955
1960
1965
1970
1975
1980
1985
1990
1995
2000
2005
2010
2015
2020
2025
2030
2035
2040
2045
2050
2055
2060
2065
2070
2075
2080
2085
2090
2095
2100
2105
2110
2115
2120
2125
2130
2135
2140
2145
2150
2155
2160
2165
2170
2175
2180
2185
2190
2195
2200
2205
2210
2215
2220
2225
2230
2235
2240
2245
2250
2255
2260
2265
2270
2275
2280
2285
2290
2295
2300
2305
2310
2315
2320
2325
2330
2335
2340
2345
2350
2355
2360
2365
2370
2375
2380
2385
2390
2395
2400
2405
2410
2415
2420
2425
2430
2435
2440
2445
2450
2455
2460
2465
2470
2475
2480
2485
2490
2495
2500
2505
2510
2515
2520
2525
2530
2535
2540
2545
2550
2555
2560
2565
2570
2575
2580
2585
2590
2595
2600
2605
2610
2615
2620
2625
2630
2635
2640
2645
2650
2655
2660
2665
2670
2675
2680
2685
2690
2695
2700
2705
2710
2715
2720
2725
2730
2735
2740
2745
2750
2755
2760
2765
2770
2775
2780
2785
2790
2795
2800
2805
2810
2815
2820
2825
2830
2835
2840
2845
2850
2855
2860
2865
2870
2875
2880
2885
2890
2895
2900
2905
2910
2915
2920
2925
2930
2935
2940
2945
2950
2955
2960
2965
2970
2975
2980
2985
2990
2995
3000
3005
3010
3015
3020
3025
3030
3035
3040
3045
3050
3055
3060
3065
3070
3075
3080
3085
3090
3095
3100
3105
3110
3115
3120
3125
3130
3135
3140
3145
3150
3155
3160
3165
3170
3175
3180
3185
3190
3195
3200
3205
3210
3215
3220
3225
3230
3235
3240
3245
3250
3255
3260
3265
3270
3275
3280
3285
3290
3295
3300
3305
3310
3315
3320
3325
3330
3335
3340
3345
3350
3355
3360
3365
3370
3375
3380
3385
3390
3395
3400
3405
3410
3415
3420
3425
3430
3435
3440
3445
3450
3455
3460
3465
3470
3475
3480
3485
3490
3495
3500
3505
3510
3515
3520
3525
3530
3535
3540
3545
3550
3555
3560
3565
3570
3575
3580
3585
3590
3595
3600
3605
3610
3615
3620
3625
3630
3635
3640
3645
3650
3655
3660
3665
3670
3675
3680
3685
3690
3695
3700
3705
3710
3715
3720
3725
3730
3735
3740
3745
3750
3755
3760
3765
3770
3775
3780
3785
3790
3795
3800
3805
3810
3815
3820
3825
3830
3835
3840
3845
3850
3855
3860
3865
3870
3875
3880
3885
3890
3895
3900
3905
3910
3915
3920
3925
3930
3935
3940
3945
3950
3955
3960
3965
3970
3975
3980
3985
3990
3995
4000
4005
4010
4015
4020
4025
4030
4035
4040
4045
4050
4055
4060
4065
4070
4075
4080
4085
4090
4095
4100
4105
4110
4115
4120
4125
4130
4135
4140
4145
4150
4155
4160
4165
4170
4175
4180
4185
4190
4195
4200
4205
4210
4215
4220
4225
4230
4235
4240
4245
4250
4255
4260
4265
4270
4275
4280
4285
4290
4295
4300
4305
4310
4315
4320
4325
4330
4335
4340
4345
4350
4355
4360
4365
4370
4375
4380
4385
4390
4395
4400
4405
4410
4415
4420
4425
4430
4435
4440
4445
4450
4455
4460
4465
4470
4475
4480
4485
4490
4495
4500
4505
4510
4515
4520
4525
4530
4535
4540
4545
4550
4555
4560
4565
4570
4575
4580
4585
4590
4595
4600
4605
4610
4615
4620
4625
4630
4635
4640
4645
4650
4655
4660
4665
4670
4675
4680
4685
4690
4695
4700
4705
4710
4715
4720
4725
4730
4735
4740
4745
4750
4755
4760
4765
4770
4775
4780
4785
4790
4795
4800
4805
4810
4815
4820
4825
4830
4835
4840
4845
4850
4855
4860
4865
4870
4875
4880
4885
4890
4895
4900
4905
4910
4915
4920
4925
4930
4935
4940
4945
4950
4955
4960
4965
4970
4975
4980
4985
4990
4995
5000
5005
5010
5015
5020
5025
5030
5035
5040
5045
5050
5055
5060
5065
5070
5075
5080
5085
5090
5095
5100
5105
5110
5115
5120
5125
5130
5135
5140
5145
5150
5155
5160
5165
5170
5175
5180
5185
5190
5195
5200
5205
5210
5215
5220
5225
5230
5235
5240
5245
5250
5255
5260
5265
5270
5275
5280
5285
5290
5295
5300
5305
5310
5315
5320
5325
5330
5335
5340
5345
5350
5355
5360
5365
5370
5375
5380
5385
5390
5395
5400
5405
5410
5415
5420
5425
5430
5435
5440
5445
5450
5455
5460
5465
5470
5475
5480
5485
5490
5495
5500
5505
5510
5515
5520
5525
5530
5535
5540
5545
5550
5555
5560
5565
5570
5575
5580
5585
5590
5595
5600
5605
5610
5615
5620
5625
5630
5635
5640
5645
5650
5655
5660
5665
5670
5675
5680
5685
5690
5695
5700
5705
5710
5715
5720
5725
5730
5735
5740
5745
5750
5755
5760
5765
5770
5775
5780
5785
5790
5795
5800
5805
5810
5815
5820
5825
5830
5835
5840
5845
5850
5855
5860
5865
5870
5875
5880
5885
5890
5895
5900
5905
5910
5915
5920
5925
5930
5935
5940
5945
5950
5955
5960
5965
5970
5975
5980
5985
5990
5995
6000
6005
6010
6015
6020
6025
6030
6035
6040
6045
6050
6055
6060
6065
6070
6075
6080
6085
6090
6095
6100
6105
6110
6115
6120
6125
6130
6135
6140
6145
6150
6155
6160
6165
6170
6175
6180
6185
6190
6195
6200
6205
6210
6215
6220
6225
6230
6235
6240
6245
6250
6255
6260
6265
6270
6275
6280
6285
6290
6295
6300
6305
6310
6315
6320
6325
6330
6335
6340
6345
6350
6355
6360
6365
6370
6375
6380
6385
6390
6395
6400
6405
6410
6415
6420
6425
6430
6435
6440
6445
6450
6455
6460
6465
6470
6475
6480
6485
6490
6495
6500
6505
6510
6515
6520
6525
6530
6535
6540
6545
6550
6555
6560
6565
6570
6575
6580
6585
6590
6595
6600
6605
6610
6615
6620
6625
6630
6635
6640
6645
6650
6655
6660
6665
6670
6675
6680
6685
6690
6695
6700
6705
6710
6715
6720
6725
6730
6735
6740
6745
6750
6755
6760
6765
6770
6775
6780
6785
6790
6795
6800
6805
6810
6815
6820
6825
6830
6835
6840
6845
6850
6855
6860
6865
6870
6875
6880
6885
6890
6895
6900
6905
6910
6915
6920
6925
6930
6935
6940
6945
6950
6955
6960
6965
6970
6975
6980
6985
6990
6995
7000
7005
7010
7015
7020
7025
7030
7035
7040
7045
7050
7055
7060
7065
7070
7075
7080
7085
7090
7095
7100
7105
7110
7115
7120
7125
7130
7135
7140
7145
7150
7155
7160
7165
7170
7175
7180
7185
7190
7195
7200
7205
7210
7215
7220
7225
7230
7235
7240
7245
7250
7255
7260
7265
7270
7275
7280
7285
7290
7295
7300
7305
7310
7315
7320
7325
7330
7335
7340
7345
7350
7355
7360
7365
7370
7375
7380
7385
7390
7395
7400
7405
7410
7415
7420
7425
7430
7435
7440
7445
7450
7455
7460
7465
7470
7475
7480
7485
7490
7495
7500
7505
7510
7515
7520
7525
7530
7535
7540
7545
7550
7555
7560
7565
7570
7575
7580
7585
7590
7595
7600
7605
7610
7615
7620
7625
7630
7635
7640
7645
7650
7655
7660
7665
7670
7675
7680
7685
7690
7695
7700
7705
7710
7715
7720
7725
7730
7735
7740
7745
7750
7755
7760
7765
7770
7775
7780
7785
7790
7795
7800
7805
7810
7815
7820
7825
7830
7835
7840
7845
7850
7855
7860
7865
7870
7875
7880
7885
7890
7895
7900
7905
7910
7915
7920
7925
7930
7935
7940
7945
7950
7955
7960
7965
7970
7975
7980
7985
7990
7995
8000
8005
8010
8015
8020
8025
8030
8035
8040
8045
8050
8055
8060
8065
8070
8075
8080
8085
8090
8095
8100
8105
8110
8115
8120
8125
8130
8135
8140
8145
8150
8155
8160
8165
8170
8175
8180
8185
8190
8195
8200
8205
8210
8215
8220
8225
8230
8235
8240
8245
8250
8255
8260
8265
8270
8275
8280
8285
8290
8295
8300
8305
8310
8315
8320
8325
8330
8335
8340
8345
8350
8355
8360
8365
8370
8375
8380
8385
8390
8395
8400
8405
8410
8415
8420
8425
8430
8435
8440
8445
8450
8455
8460
8465
8470
8475
8480
8485
8490
8495
8500
8505
8510
8515
8520
8525
8530
8535
8540
8545
8550
8555
8560
8565
8570
8575
8580
8585
8590
8595
8600
8605
8610
8615
8620
8625
8630
8635
8640
8645
8650
8655
8660
8665
8670
8675
8680
8685
8690
8695
8700
8705
8710
8715
8720
8725
8730
8735
8740
8745
8750
8755
8760
8765
8770
8775
8780
8785
8790
8795
8800
8805
8810
8815
8820
8825
8830
8835
8840
8845
8850
8855
8860
8865
8870
8875
8880
8885
8890
8895
8900
8905
8910
8915
8920
8925
8930
8935
8940
8945
8950
8955
8960
8965
8970
8975
8980
8985
8990
8995
9000
9005
9010
9015
9020
9025
9030
9035
9040
9045
9050
9055
9060
9065
9070
9075
9080
9085
9090
9095
9100
9105
9110
9115
9120
9125
9130
9135
9140
9145
9150
9155
9160
9165
9170
9175
9180
9185
9190
9195
9200<br

(A) a hydrogen atom,

(B) methyl, or

5

(C) a group of the formula $-OR^{33}$, wherein R^{33} is a hydrogen atom methyl;

R^4 is Cl or trifluoromethyl;

10 X is $=N-$ or $=CR^5-$,

wherein R^5 is a hydrogen, fluorine, chlorine, bromine or iodine atom, methyl or trifluoromethyl;

R^6 is a hydrogen, fluorine, chlorine, bromine or iodine atom, methyl, cyano, nitro or

15 trifluoromethyl, with the condition that when X is N or $=CH-$, R^6 is chlorine or trifluoromethyl;

R^7 , R^8 and R^9 are each, independently:

20 (A) a hydrogen atom,

(B) an oxo group, or

(C) R^{34} , OR^{34} , NHR^{34} , COR^{34} , $CONHR^{34}$, $COOR^{34}$, SO_2R^{34} , or SR^{34}

25

wherein R^{34} is defined as:

(i) a hydrogen atom,

30

(ii) branched or unbranched alkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, which alkyl or cycloalkyl group may be mono- or polysubstituted with:

(a) oxo,

(b) phenyl,

5 wherein one or more hydrogen atoms of said phenyl group may be optionally and independently replaced with:

(1) alkyl of 1 to 3 carbon atoms,

10 (2) -COOH,

(3) -SO₂OH,

(4) -PO(OH)₂,


15 (5) a group of the formula -COOR³⁵, wherein R³⁵ is straight or branched alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,

20 (6) a group of the formula -NR³⁶R³⁷, wherein R³⁶ and R³⁷ are each independently a hydrogen atom, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms or acyl of 1 to 7 carbon atoms, or wherein R³⁶ and R³⁷ constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom between them form a heterocyclic ring,

25 (7) a group of the formula -CONR³⁸R³⁹, wherein R³⁸ and R³⁹ are each independently a hydrogen atom, alkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, or wherein R³⁸ and R³⁹ constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms

which together with the nitrogen atom between them form a heterocyclic ring,

- (8) a group of the formula $-OR^{40}$, wherein R⁴⁰ is a hydrogen atom, or an alkyl or acyl group of 1 to 7 carbon atoms,
 - (9) a group of the formula $-SR^{41}$, wherein R⁴¹ is a hydrogen atom, or an alkyl or acyl group of 1 to 7 carbon atoms,
 - (10) cyano, or
 - (11) an amidino group of the formula




wherein R⁴², R⁴³ and R⁴⁴ are each, independently, a hydrogen atom or alkyl of 1 to 3 carbon atoms and wherein two of R⁴², R⁴³ and R⁴⁴ may additionally constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom(s) between them form a heterocyclic ring.

- (c) a group of the formula --COOR^{45} , wherein R^{45} is straight or branched alkyl of 1 to 7 carbon atoms or cycloalkyl of 3 to 6 carbon atoms,
 - (d) cyano,

- 5
- (e) a group of the formula $-\text{CONR}^{46}\text{R}^{47}$, wherein R^{46} and R^{47} are each, independently, a hydrogen atom, alkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, or wherein R^{46} and R^{47} constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom between them form a heterocyclic ring,
- 10
- (f) a group of the formula $-\text{OR}^{48}$, wherein R^{48} is a hydrogen atom, or an alkyl or acyl group of 1 to 7 carbon atoms,
- 15
- (g) a group of the formula $-\text{SR}^{49}$, wherein R^{49} is a hydrogen atom, or an alkyl or acyl group of 1 to 7 carbon atoms,
- 20
- (h) a group of the formula $-\text{NR}^{50}\text{R}^{51}$, wherein R^{50} and R^{51} are each, independently,
- 25
- (1) a hydrogen atom,
- (2) alkyl or acyl of 1 to 7 carbon atoms or cycloalkyl of 3 to 7 carbon atoms,
- (3) a group of the formula $-(\text{CH}_2)_t\text{COOH}$, wherein t is 0, 1 or 2, or
- (4) a group of the formula $-(\text{CH}_2)_u\text{COOR}^{52}$, wherein u is 0, 1 or 2, wherein R^{52} is straight or branched alkyl of 1 to 6 carbon atoms,
- 30
- or wherein R^{50} and R^{51} constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom between them form a heterocyclic ring, or

- (i) a quaternary group of the formula




5 wherein R^{53} , R^{54} and R^{55} are each, independently, a branched or unbranched alkyl group of 1 to 7 carbon atoms and Q^- is a chlorine, bromine or iodine counterion,

10 (iii) a branched or unbranched carboxylic acid group of 2 to 6 carbon atoms,

(iv) a branched or unbranched phosphonic acid group of 2 to 6 carbon atoms,

15 (v) a branched or unbranched sulfonic acid group of 2 to 6 carbon atoms,

(vi) an amidino group of the formula




20

wherein r is 2, 3, 4, 5 or 6, and

25

R^{56} , R^{57} and R^{58} are each, independently, a hydrogen atom or alkyl of 1 to 3 carbon atoms, and wherein two of R^{56} , R^{57} and R^{58} may additionally constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom(s) between them form a heterocyclic ring,

(vii) a guanidino group of the formula



wherein s is 2, 3, 4, 5 or 6, and

5

R^{59} , R^{60} , R^{61} and R^{62} are each, independently, a hydrogen atom or alkyl of 1 to 3 carbon atoms, and wherein two of R^{59} , R^{60} , R^{61} and R^{62} may additionally constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom(s) between them form a heterocyclic ring,

10

(viii) phenyl,

15

wherein one or more hydrogen atoms of said phenyl group may be optionally and independently replaced with:

20

(a) alkyl of 1 to 3 carbon atoms,

(b) -COOH,


(c) -SO₂OH,

(d) -PO(OH)₂,

25

(e) a group of the formula -COOR⁶³, wherein R⁶³ is straight or branched alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,

- 5
- (f) a group of the formula $-NR^{64}R^{65}$, wherein R⁶⁴ and R⁶⁵ are each, independently, a hydrogen atom, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms or acyl of 1 to 7 carbon atoms, or wherein R⁶⁴ and R⁶⁵ constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom between them form a heterocyclic ring,
- 10
- (g) a group of the formula $-CONR^{66}R^{67}$, wherein R⁶⁶ and R⁶⁷ are each, independently, a hydrogen atom, alkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, or wherein R⁶⁶ and R⁶⁷ constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom between them form a heterocyclic ring,
- 15
- (h) a group of the formula $-OR^{68}$, wherein R⁶⁸ is a hydrogen atom, or an alkyl or acyl group of 1 to 7 carbon atoms,
- 20
- (i) a group of the formula $-SR^{69}$, wherein R⁶⁹ is a hydrogen atom, or an alkyl or acyl group of 1 to 7 carbon atoms,
- (j) cyano,
- (k) or, an amidino group of the formula
- 25



wherein R⁷⁰, R⁷¹ and R⁷² are each, independently, a hydrogen atom or alkyl of 1 to 3 carbon atoms, and wherein

two of R⁷⁰, R⁷¹ and R⁷² may additionally constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom(s) between them form a heterocyclic ring;

5

with the proviso that R¹ and R² are in the trans configuration;

or a pharmaceutically acceptable salt thereof.

10

3. A compound of the formula I, in accordance with claim 1, wherein:

m is 0 or 1,

15 n is 0 or 1, and

m + n is equal to either 1 or 2;

Y is an oxygen atom;

20

Z is an oxygen atom;

R¹ is:

25

(A) a hydrogen atom,

(B) methyl, or

30

(C) a group of the formula -OR¹³, wherein R¹³ is a an alkyl or acyl group of 1 to 2 carbon atoms;

R² is:

phenyl,

wherein one or more of the hydrogen atoms of said phenyl group may be optionally and independently replaced with:

5

- (i) R¹⁴, which is aryl selected from the class consisting of phenyl, 3-pyridyl, or 5-pyrimidinyl,

10

wherein one or more of the hydrogen atoms of said R¹⁴ aryl group may be optionally and independently replaced with:

15

- (a) methyl,

- (b) cyano,

- (c) nitro, or

- (d) halogen,

20

- (ii) methyl, which may be mono- or polysubstituted with fluorine atoms,

25

- (iii) branched or unbranched alkyl of 2 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, which alkyl or cycloalkyl group may be mono- or polysubstituted with halogen or oxo,

30

- (iv) a group of the formula -COOR²², wherein R²² is straight or branched alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,

- (v) a group of the formula -CONR²⁵R²⁶, wherein R²⁵ and R²⁶ are each, independently, a hydrogen atom, alkyl or

fluoroalkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, or wherein R²⁵ and R²⁶ constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom between them form a heterocyclic ring,

5

(vi) a group of the formula -COR²⁷, wherein R²⁷ is a hydrogen atom, straight or branched alkyl of 1 to 5 carbon atoms, or cycloalkyl of 3 to 5 carbon atoms,

10

(vii) a group of the formula -OR²⁸, wherein R²⁸ is a hydrogen atom, an alkyl, fluoroalkyl or acyl group of 1 to 7 carbon atoms,

15

(viii) a group of the formula -SR²⁹, wherein R²⁹ is a hydrogen atom, an alkyl, fluoroalkyl or acyl group of 1 to 7 carbon atoms,

(ix) cyano,

20

(x) nitro, or

(xi) halogen,

25

R³ is:

(A) a hydrogen atom,

30

(B) methyl, or

(C) a group of the formula -OR³³, wherein R³³ is a hydrogen atom methyl;

R⁴ is Cl or trifluoromethyl;

X is =N- or =CR⁵-,

5 wherein R⁵ is a hydrogen, fluorine, chlorine, bromine or iodine atom, methyl or trifluoromethyl;

10 R⁶ is a hydrogen, fluorine, chlorine, bromine or iodine atom, methyl, cyano, nitro or trifluoromethyl, with the condition that when X is N or =CH-, R⁶ is chlorine or trifluoromethyl;

R⁷, R⁸ and R⁹ are each, independently:

(A) a hydrogen atom,

15

(B) an oxo group, or

(C) R³⁴, OR³⁴, NHR³⁴, COR³⁴, CONHR³⁴, COOR³⁴, SO₂R³⁴, or SR³⁴

20

wherein R³⁴ is defined as:

(i) a hydrogen atom,

25

(ii) branched or unbranched alkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, which alkyl or cycloalkyl group may be mono- or polysubstituted with:

30

(a) oxo,

(b) phenyl,

wherein one or more hydrogen atoms of said phenyl group may be optionally and independently replaced with:

- (1) alkyl of 1 to 3 carbon atoms,
- 5 (2) -COOH,
- (3) -SO₂OH,
- (4) -PO(OH)₂,
- 10 (5) a group of the formula -COOR³⁵, wherein R³⁵ is straight or branched alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,
- 15 (6) a group of the formula -NR³⁶R³⁷, wherein R³⁶ and R³⁷ are each independently a hydrogen atom, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms or acyl of 1 to 7 carbon atoms, or wherein R³⁶ and R³⁷ constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom between them form a heterocyclic ring,
- 20 (7) a group of the formula -CONR³⁸R³⁹, wherein R³⁸ and R³⁹ are each independently a hydrogen atom, alkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, or wherein R³⁸ and R³⁹ constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom between them form a heterocyclic ring,

(8) a group of the formula $-OR^{40}$, wherein R⁴⁰ is a hydrogen atom, or an alkyl or acyl group of 1 to 7 carbon atoms,


5

(9) a group of the formula $-SR^{41}$, wherein R⁴¹ is a hydrogen atom, or an alkyl or acyl group of 1 to 7 carbon atoms,

10

(10) cyano, or

(11) an amidino group of the formula



15

wherein R⁴², R⁴³ and R⁴⁴ are each, independently, a hydrogen atom or alkyl of 1 to 3 carbon atoms and wherein two of R⁴², R⁴³ and R⁴⁴ may additionally constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom(s) between them form a heterocyclic ring,

20

(c) a group of the formula $-COOR^{45}$, wherein R⁴⁵ is straight or branched alkyl of 1 to 7 carbon atoms or cycloalkyl of 3 to 6 carbon atoms,

25

(d) cyano,

(e) a group of the formula $-CONR^{46}R^{47}$, wherein R⁴⁶ and R⁴⁷ are each, independently, a hydrogen atom, alkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, or

wherein R⁴⁶ and R⁴⁷ constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom between them form a heterocyclic ring,

- 5 (f) a group of the formula $-OR^{48}$, wherein R⁴⁸ is a hydrogen atom, or an alkyl or acyl group of 1 to 7 carbon atoms,

10 (g) a group of the formula $-SR^{49}$, wherein R⁴⁹ is a hydrogen atom, or an alkyl or acyl group of 1 to 7 carbon atoms,

15 (h) a group of the formula $-NR^{50}R^{51}$, wherein R⁵⁰ and R⁵¹ are each, independently,

(1) a hydrogen atom,

(2) alkyl or acyl of 1 to 7 carbon atoms or cycloalkyl of 3 to 7 carbon atoms,


(3) a group of the formula $-(CH_2)_tCOOH$, wherein t is 0, 1 or 2, or

(4) a group of the formula $-(CH_2)_uCOOR^{52}$, wherein u is 0, 1 or 2, wherein R⁵² is straight or branched alkyl of 1 to 6 carbon atoms,

20 or wherein R⁵⁰ and R⁵¹ constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom between them form a heterocyclic ring, or

25 (i) a quaternary group of the formula

30



wherein R⁵³, R⁵⁴ and R⁵⁵ are each, independently, a branched or unbranched alkyl group of 1 to 7 carbon atoms and Q⁻ is a chlorine, bromine or iodine counterion,

5

(iii) a branched or unbranched carboxylic acid group of 2 to 6 carbon atoms,


10

(iv) a branched or unbranched phosphonic acid group of 2 to 6 carbon atoms,

(v) a branched or unbranched sulfonic acid group of 2 to 6 carbon atoms,

15

(vi) an amidino group of the formula




wherein r is 2, 3, 4, 5 or 6, and

20 R⁵⁶, R⁵⁷ and R⁵⁸ are each, independently, a hydrogen atom or alkyl of 1 to 3 carbon atoms, and wherein two of R⁵⁶, R⁵⁷ and R⁵⁸ may additionally constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom(s) between them form a heterocyclic ring.

25

(vii) a guanidino group of the formula



wherein s is 2, 3, 4, 5 or 6, and

R⁵⁹, R⁶⁰, R⁶¹ and R⁶² are each, independently, a hydrogen atom
 5 or alkyl of 1 to 3 carbon atoms, and wherein two of R⁵⁹, R⁶⁰, R⁶¹
 and R⁶² may additionally constitute a saturated hydrocarbon bridge
 of 3 to 5 carbon atoms which together with the nitrogen atom(s)
 between them form a heterocyclic ring,

10 (viii) phenyl,

wherein one or more hydrogen atoms of said phenyl group may be
 optionally and independently replaced with:

15 (a) alkyl of 1 to 3 carbon atoms,

(b) -COOH,

(c) -SO₂OH,

20 (d) -PO(OH)₂,

(e) a group of the formula -COOR⁶³, wherein R⁶³ is straight or
 branched alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5
 25 carbon atoms,

(f) a group of the formula -NR⁶⁴R⁶⁵, wherein R⁶⁴ and R⁶⁵ are
 each, independently, a hydrogen atom, alkyl of 1 to 6 carbon
 atoms, cycloalkyl of 3 to 6 carbon atoms or acyl of 1 to 7

carbon atoms, or wherein R⁶⁴ and R⁶⁵ constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom between them form a heterocyclic ring,

5

- (g) a group of the formula $-\text{CONR}^{66}\text{R}^{67}$, wherein R⁶⁶ and R⁶⁷ are each, independently, a hydrogen atom, alkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, or wherein R⁶⁶ and R⁶⁷ constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom between them form a heterocyclic ring,

10

- (h) a group of the formula $-\text{OR}^{68}$, wherein R⁶⁸ is a hydrogen atom, or an alkyl or acyl group of 1 to 7 carbon atoms,


15

- (i) a group of the formula $-\text{SR}^{69}$, wherein R⁶⁹ is a hydrogen atom, or an alkyl or acyl group of 1 to 7 carbon atoms,

- (j) cyano,

20

- (k) or, an amidino group of the formula



25

wherein R⁷⁰, R⁷¹ and R⁷² are each, independently, a hydrogen atom or alkyl of 1 to 3 carbon atoms, and wherein two of R⁷⁰, R⁷¹ and R⁷² may additionally constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which

together with the nitrogen atom(s) between them form a heterocyclic ring;

with the proviso that R¹ and R² are in the trans configuration;

5

or a pharmaceutically acceptable salt thereof.

4. A compound of the formula I, in accordance with claim 1, wherein:

10

m is 0 or 1,

n is 0 or 1, and

15 m + n is equal to either 1 or 2;

Y is an oxygen atom;

Z is an oxygen atom;

20

R¹ is:

(A) a hydrogen atom, or

25

(B) methyl;

R² is:

phenyl,

30

wherein one or more of the hydrogen atoms of said phenyl group may be optionally and independently replaced with:

(i) R^{14} , which is aryl selected from the class consisting of phenyl, 3-pyridyl, or 5-pyrimidinyl,

5 wherein one or more of the hydrogen atoms of said R^{14} aryl group may be optionally and independently replaced with:

(a) methyl,

(b) cyano,

10 (c) nitro, or

(d) halogen,

15 (ii) cyano,

(iii) nitro, or

(iv) halogen;

20

R^3 is a hydrogen atom;

R^4 is Cl;

25 X is =CH-;

R^6 is Cl;

R^7 , R^8 and R^9 are each, independently:

30

(A) a hydrogen atom,

(B) an oxo group, or

(C) R³⁴ or OR³⁴,

5 wherein R³⁴ is defined as:

(i) a hydrogen atom,

10 (ii) branched or unbranched alkyl of 1 to 6 carbon atoms or cycloalkyl
of 3 to 6 carbon atoms, which alkyl or cycloalkyl group may be
mono- or polysubstituted with:

(a) oxo,

15 (b) phenyl,
wherein one or more hydrogen atoms of said phenyl group
may be optionally and independently replaced with:

(1) alkyl of 1 to 3 carbon atoms,

20 (2) -COOH,


25 (3) a group of the formula -NR³⁶R³⁷, wherein R³⁶ and
R³⁷ are each independently a hydrogen atom, alkyl
of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon
atoms or acyl of 1 to 7 carbon atoms, or wherein R³⁶
and R³⁷ constitute a saturated hydrocarbon bridge of
3 to 5 carbon atoms which together with the nitrogen
atom between them form a heterocyclic ring,

30

(4) a group of the formula $-OR^{40}$, wherein R⁴⁰ is a hydrogen atom, or an alkyl or acyl group of 1 to 7 carbon atoms, or

5

(5) an amidino group of the formula



10

wherein R⁴², R⁴³ and R⁴⁴ are each, independently, a hydrogen atom or alkyl of 1 to 3 carbon atoms and wherein two of R⁴², R⁴³ and R⁴⁴ may additionally constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom(s) between them form a heterocyclic ring,

15

(c) a group of the formula $-OR^{48}$, wherein R⁴⁸ is a hydrogen atom, or an alkyl or acyl group of 1 to 7 carbon atoms,

20

(d) a group of the formula $-NR^{50}R^{51}$, wherein R⁵⁰ and R⁵¹ are each, independently,

25

(1) a hydrogen atom,

(2) alkyl or acyl of 1 to 7 carbon atoms or cycloalkyl of 3 to 7 carbon atoms, or

(3) a group of the formula $-(CH_2)_tCOOH$, wherein t is 0, 1 or 2,


or wherein R⁵⁰ and R⁵¹ constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom between them form a heterocyclic ring, or

5

- (iii) a branched or unbranched carboxylic acid group of 2 to 6 carbon atoms,

10

- (iv) an amidino group of the formula



wherein r is 2, 3, 4, 5 or 6, and

15

R⁵⁶, R⁵⁷ and R⁵⁸ are each, independently, a hydrogen atom or alkyl of 1 to 3 carbon atoms, and wherein two of R⁵⁶, R⁵⁷ and R⁵⁸ may additionally constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom(s) between them form a heterocyclic ring.

20

- (v) phenyl,

wherein one or more hydrogen atoms of said phenyl group may be optionally and independently replaced with:

25

- (a) alkyl of 1 to 3 carbon atoms,

- (b) -COOH,


5

10

20

25

- (c) a group of the formula $-NR^{64}R^{65}$, wherein R⁶⁴ and R⁶⁵ are each, independently, a hydrogen atom, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms or acyl of 1 to 7 carbon atoms, or wherein R⁶⁴ and R⁶⁵ constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom between them form a heterocyclic ring,
- (d) a group of the formula $-OR^{68}$, wherein R⁶⁸ is a hydrogen atom, or an alkyl or acyl group of 1 to 7 carbon atoms,
- (e) or, an amidino group of the formula



15

wherein R⁷⁰, R⁷¹ and R⁷² are each, independently, a hydrogen atom or alkyl of 1 to 3 carbon atoms, and wherein two of R⁷⁰, R⁷¹ and R⁷² may additionally constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom(s) between them form a heterocyclic ring;

with the proviso that R¹ and R² are in the trans configuration;

or a pharmaceutically acceptable salt thereof.

5. A compound of the formula I, in accordance with claim 1, wherein:

m is 0;

n is 1;

5 Y is an oxygen atom;

Z is an oxygen atom;

R¹ is:

10

- (A) a hydrogen atom, or
- (B) methyl;

15 R² is:

phenyl,

wherein one or more of the hydrogen atoms of said phenyl group may be optionally and independently replaced with:

20

- (i) R¹⁴, which is aryl selected from the class consisting of phenyl, 3-pyridyl, or 5-pyrimidinyl,
- (ii) cyano,
- (iii) nitro, or
- (iv) halogen;

30

R³ is a hydrogen atom;

R⁴ is Cl;

X is =CH-;

5 R⁶ is Cl;

R⁷, R⁸ and R⁹ are each, independently:

- (A) a hydrogen atom,
- 10 (B) an oxo group, or
- (C) R³⁴ or OR³⁴,

15 wherein R³⁴ is defined as:

- (i) a hydrogen atom,
- (ii) branched or unbranched alkyl of 1 to 6 carbon atoms or cycloalkyl
20 of 3 to 6 carbon atoms, which alkyl or cycloalkyl group may be mono- or polysubstituted with a group of the formula -OR⁴⁸, wherein R⁴⁸ is a hydrogen atom, or an alkyl of 1 to 7 carbon atoms;

25 with the proviso that R¹ and R² are in the trans configuration;

and pharmaceutically acceptable salts thereof.

or a pharmaceutically acceptable salt thereof.

30

6. A compound of the formula I, in accordance with claim 1, selected from the group consisting of:

2-(3,5-Dichlorophenyl)-7-(R*)- phenyl-7a-(R*)-tetrahydropyrrolo[1,2-c]imidazole-1,3-dione;

5 2-(3,5-Dichlorophenyl)- 7a-(R*)-methyl-7-(R*)- phenyl-tetrahydropyrrolo[1,2-c]imidazole-1,3-dione;

7-(R*)(-4-Bromophenyl)-2-(3,5-dichlorophenyl)-7a-(R*)-tetrahydropyrrolo[1,2-c]imidazole-1,3-dione;

10 2-(3,5-dichlorophenyl)-8a-(R*)-methyl-8-(R*)-phenyl-tetrahydroimidazo[1,5-b]pyridine-1,3-dione;

2-(3,5-dichlorophenyl)-8a-(S*)-methoxy-8-(R*)-phenyl-tetrahydroimidazo[1,5-b]pyridine-1,3-dione;

7-(R*)(-4-Bromophenyl)-2-(3,5-dichlorophenyl)-7a-(R*)-methyl-tetrahydropyrrolo[1,2-c]imidazole-1,3-dione;

15 2-(3,5-dichlorophenyl)- 7-(R*)-[4-(3-pyridyl)phenyl]-7a-(R*)methyl-tetrahydropyrrolo[1,2-c]imidazole-1,3-dione;

7-(R*)(-4-Bromophenyl)-2-(3,5-dichlorophenyl)-6-(S*)-hydroxy-7a-(R*)-tetrahydropyrrolo[1,2-c]imidazole-1,3-dione;


20 7-(R*)(-4-Bromophenyl)-2-(3,5-dichlorophenyl)-7a-(R*)-allyl-tetrahydropyrrolo[1,2-c]imidazole-1,3-dione; and,

7-(R*)(-4-Bromophenyl)-2-(3,5-dichlorophenyl)-5-(S*)-hydroxy-7a-(R*)-methyl-tetrahydropyrrolo[1,2-c]imidazole-1,3-dione;

or a pharmaceutically acceptable salt thereof.

25

7. A compound of the formula I, in accordance with claim 1, 2, 3, 4, 5 or 6 with the absolute stereochemistry depicted below in formula Ia.



8. A method for the treatment or prophylaxis of inflammatory or immune cell-mediated diseases which comprises administering to a host in need of such treatment or prophylaxis a therapeutic or prophylactic amount of a compound of the formula I in accordance with claim 1, 2, 3, 4, 5 or 6.
- 10 9. The method of claim 8 wherein the disease or condition is selected from the group consisting of adult respiratory distress syndrome, shock, oxygen-toxicity, multiple organ injury syndrome secondary to septicemia, multiple organ injury syndrome secondary to trauma, reperfusion injury of tissue due to cardiopulmonary bypass, myocardial infarction or use with thrombolysis agents, acute glomerulonephritis, vasculitis, reactive arthritis, 15 dermatosis with acute inflammatory components, stroke, thermal injury, hemodialysis, leukapheresis, ulcerative colitis, necrotizing enterocolitis and granulocyte transfusion associated syndrome.
- 20 10. The method of claim 8 wherein the disease or condition is selected from the group consisting of psoriasis, organ/tissue transplant rejection, graft vs. host reactions and autoimmune diseases including Raynaud's syndrome, autoimmune thyroiditis, dermatitis, multiple sclerosis, rheumatoid arthritis, insulin-dependent diabetes mellitus, uveitis, inflammatory bowel disease including Crohn's disease and ulcerative colitis; and systemic 25 lupus erythematosus.

11. The method of claim 8 wherein the disease or condition is asthma.

12. The method of claim 8 wherein the condition is toxicity associated with cytokine
5 therapy.

13. A pharmaceutical composition comprising a compound of the formula I, in
accordance with claim 1, 2, 3, 4, 5 or 6.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/17752

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 31/55
US CL : 514/214, 299; 540/593; 546/112

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/214, 299; 540/593; 546/112

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EAST, REGISTRY, MARPAT

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Database CA on STN, Chemical Abstracts, (Columbus OH, USA) No. 128:204801, HOLLINSHEAD, S. et al. 'Combinatorial process for preparing substituted pyrrolidine libraries', abstract WO 9808813, March 1998.	1-13
A	Database CA on STN, Chemical Abstracts, (Columbus OH, USA) No. 124:145896, Drewes, M et al. 'Preparation of 4-(heterocyclo)-2-(sulfonamido)benzonitrile selective herbicides', abstract DE 4414568, November 1995.	1-13

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier application or patent published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

17 August 2000 (17.08.2000)

Date of mailing of the international search report

29 SEP 2000

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Faxsimile No. (703)305-3230

Authorized officer

D. Margaret Seaman

Telephone No. 703-308-1235